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ABSTRACT 
 
BACKGROUND: 
  Acute bronchiolitis is the most common condition in children with 
rapid respiration, chest retractions, and wheezing.1 RSV is the most 
common cause for acute bronchiolitis. Up to 3% of all children are 
hospitalized with acute bronchiolitis in their first year of life.9 Despite the 
high prevalence of acute bronchiolitis, little consensus exists on the 
optimal management of the disease.10 Management of acute bronchiolitis 
is mainly supportive. Various bronchodilators have been used in the 
treatment. None have been found to be efficacious. 
 
AIMS AND OBJECTIVES: 
To compare the effectiveness of nebulised adrenaline ,nebulised 
salbutamol and  nebulised  budesonide in the treatment of acute 
bronchiolitis in terms of clinical improvement, decrease in respiratory   
distress and duration of hospital stay. 
 
 
 
 
 MATERIALS AND METHODS: 
Children in the age group of 2 months  to 2 years with bronchiolitis 
admitted in the Pediatric ward, Government Mohan Kumaramangalam  
Medical College Hospital,salem.It is a Hospital based prospective 
interventional double  blinded randomized trial. 
 All cases of acute bronchiolitis with a Respiratory Distress 
Assessment Instrument (RDAI) score of 4 to 15 [on a scale of 0 (mild) to 
17 (severe) were included.The children were randomised into 3 groups. 
The drugs A, B and C were given according to the random number. The 
drugs were not disclosed initially. All children received supportive care. 
 
 STATISTICAL ANALYSIS: 
Data were analyzed using SPSS 23. Statistical methods used were t 
test, chi square test and Anova . 
RESULTS:  
Out of 90 enrolled in our study, 30 were given drug A,another 30 
were given drug B   and another 30 were given drug C. There was  
improvement in all the 3 Groups in terms of HR, RR, and RDAI. GROUP 
B had significant improvement compared to other Groups. Group B drug 
was found to be ADRENALINE. 
  CONCLUSION:  
Group B that is use of nebulised adrenaline brought about 
symptomatic improvement in the decrease in tachycardia, tachypnoea and 
RDAI score and the difference was significant. Hence Group B, nebulised 
adrenaline was found to be effective in acute control of symptoms. 
However, saturation and duration of hospital stay did not vary between 
the groups. 
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PROFORMA 
 
TITLE OF THE STUDY: 
COMPARISON OF NEBULISED ADRENALINE, NEBULISED SALBUTAMOL 
AND NEBULISED BUDESONIDE IN THE TREATMENT OF BRONCHIOLITIS. 
 
By :  Dr. SHANMUGA PRIYADHARSINI.   
 
GUIDE: Dr. SAMPATHKUMAR.P 
 
CASE No: 
NAME : 
AGE: 
SEX 
ADDRESS: 
 
IP No: 
 
DATE OF ADMISSION: 
 
PRESENTING COMPLAINTS: PRESENT/ABSENT 
 DURATION 
1. Cold, Rhinorrhea  :  
2. Cough   : 
3. Fever    : 
4. Wheeze   : 
5. Fast breathing  : 
6. Chest Indrawing  : 
7. Other complaints   :  if any specify  : 
PAST HISTORY :  
Any history of similar illness in the past   : Y/N 
Any history of receiving corticosteroids in the past  : Y/N 
FAMILY HISTORY : 
 Any history of asthma in the family members : Y/N 
BIRTH HISTORY  :  
BENERALK PHYSICAL EXAMINATION: 
VITAL SIGNS 
 Temperature  : 
 Pulse    : 
 Respiratory rate  : 
 Heart rate   : 
 SpO2 (Without O2) : 
 (With O2)   : 
ANTHROPOMETRY : 
PARAMETER OBSERVED EXPECTED REMARKS 
Height     
Weight    
Head Circumference    
Chest Circumference    
MAC    
Pallor, Icterus, Cyanosis, Clubbin, Lymphadenopathy, Edema. 
 
OTHER FINDINGS (If any)  : 
SYSTEMIC EXAMINATION :  
RESPIRATORY SYSTEM  : 
CORDIOVASCULAR SYSTEM : 
PER ABDOMEN    : 
CENTRAL NERVOUS SYSTEM : 
CLINICAL DIAGNOSIS  : 
  
INVESTIGATIONS : 
1. Hb : 
2. Total WBC : 
3. Differential count : 
4. Chest X-Ray : 
5. Urine routine : 
6. Blood Culture : 
7. Urine Culture :  
TREATMENT  RECEIVED : 
DID THE PATIENT RECEIVE ANTOBIOTICS (if  Yes, why?) 
COURSE IN THE HOSPITAL : 
  
INFORMED CONSENT FORM 
 
 I have read the fore going information, or it has been read to me.  I  
have been explained about the disease, risks involved, various treatments 
available for it in my own vernacular language.  I have had the 
opportunity to ask questions about it and any questions that I have asked 
have been answered to my satisfaction.  I consent voluntarily for my child 
to participate as a participant in this study. 
 I understand that the information collected about my child foirm 
my participation and medical information hence gathered may be looked 
at by responsible individuals and regulatory authorities where it is 
relevant, in my child taking part in research.  I give permission for these 
individuals to have access to my child’s records. 
 
         Signature   
 KEYS TO MASTERCHART 
A   Nebulised adrenaline group 
 B   Oral dexamethasone group  
C   Nebulised adrenaline + Oral dexamethasone group  
M   Male 
 F   Female 
 P   Present 
 N   No 
 Y   Yes 
 Ph. No  Phone number 
 Mnths  Months  
V   Vaginal delivery  
C   Caesarean delivery  
Wt.   Weight 
 NICU  Neonatal Intensive Care Unit  
Temp.  Temperature 
 PR   Pulse Rate 
 HR   Heart Rate 
 RR   Respiratory Rate 
 SpO2RA  Saturation at Room Air  
SpO2 O2  Saturation with oxygen  
RDAI   Respiratory Distress Assessment Instrument  
SAM   Severe Acute Malmutrition 
 PICCLE  Pallor, Icterus, Cyanosis, Clubbing, Lymphadenopathy 
 ICR   InterCostal Retractions  
SCR   SubCostal Retractions 
 Crepts  Crepitations  
Hb%   Haemoglobin % 
 TC   Total Count  
DC   Differential Count 
 P   Polymorphs 
 L   Lymphocytes 
 E   Eosinophils  
M   Monocytes  
CXR   Chest X-Ray  
NAD   No Abnormalities Detected  
Rt.   Right side  
Lt.   Left side 
h/o   History of neb. Nebulisation 
 BA   Birth Asphyxia 
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INTRODUCTION 
 
            Acute bronchiolitis means inflammation of the bronchioles. In a 
child younger than 2 years of age, bronchiolitis refers  to a clinical 
syndrome usually characterized by rapid respiration, chest retractions, 
and wheezing1. Acute bronchiolitis is one of the major causes for hospital 
admissions of infants younger than 1 year of age; most commonly, it 
affects infants between  2 and 6 months.2 The infant characteristically 
presents with a viral infection with  rhinorrhoea, cough, a low-grade fever 
and within 1 or 2 days, the symptoms are followed by  onset of rapid 
respiration, chest retractions and wheezing. The infant can show 
irritability, poor feeding, and vomiting.3  
 In very young or premature infants, however, the presentation of 
disease is atypical and has features of severe pneumonia.4 In general, only 
infants older than 1 month develop the clinical syndrome of acute 
bronchiolitis.5 Risk factor of acute bronchiolitis usually include low levels 
of antibodies in cord blood, gender, birth month, absence of or minimal 
breast feeding, crowded  living conditions, being a twin or triplet, low 
socio-economic status, and  cigarette smoking mothers.6-8 . More than 
50% of cases of bronchiolitis are caused by RSV. Others include 
parainfluenza, adenovirus, mycoplasma, rhinovirus, human  
metapneumovirus and bocavirus.11,13 Around 3% of all  children are  
2 
 
hospitalized with acute bronchiolitis in their first year of life.9 Despite the 
high  prevalence of acute bronchiolitis, little consensus exists on the 
optimal  management of the disease.10  
Management of acute bronchiolitis is mainly supportive. 
Humidified oxygen is  delivered via nasal cannulae or into a headbox; the 
concentration required is determined  by pulse-oximetry. The infant is 
monitored for apnoea.  Nebulised  bronchodilators, such as salbutamol or 
ipratropium, though often used,there is no evidence that bronchodilators 
have a role in the  treatment of bronchiolitis. Fluids may need to be given 
by nasogastric tube or intravenously.11 Mechanical ventilation may be 
required in about 2% of infants admitted to hospital.10 Various other 
treatments have been proposed for acute bronchiolitis. They are other 
bronchodilators like adrenaline, inhaled and systemic steroids, 
aerosolised human DNAase, ribavirin, antibiotics, leukotriene receptor 
antagonists, heliox, ventilation,immunoglobulins. Among them the use of 
nebulised adrenaline, nebulised budesonide  in the treatment of 
bronchiolitis in infants is still in controversy.10 Hence the current study 
was undertaken to compare the efficacy of nebulised adrenaline 
,nebulised salbutamol and nebulised budesonide in decreasing the 
respiratory distress and duration of  hospital stay among children with 
acute bronchiolitis.  
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AIMS AND OBJECTIVES  
To compare the effectiveness of nebulised adrenaline,nebulised 
salbutamol and  nebulised  budesonide in the treatment of acute 
bronchiolitis in terms of clinical improvement, decrease in respiratory   
distress and duration of hospital stay. 
 
 
 
 
 
 
 
 
 
                                      
  
 
 
4 
 
REVIEW OF LITERATURE 
 
 DEFINITION  
Acute bronchiolitis is  defined as the first  episode of respiratory 
distress,usually viral, accompanied by  cough, coryza  and wheezing.12 It 
is a clinically diagnosed respiratory condition presenting with breathing 
difficulties, cough, poor  feeding, irritability and in the very young 
infants, apnoea. 
 The American Academy of Pediatrics (AAP) guidelines defines 
acute bronchiolitis  as “a constellation of clinical symptoms and signs 
including a viral upper respiratory prodrome followed by increased 
respiratory effort and wheezing in children less than 2 years of age.”13,15 
 The Scottish Intercollegiate Guidelines Network defines acute 
bronchiolitis as “a seasonal viral illness characterised by fever, nasal 
discharge and dry wheezy cough; examination of the chest revealing 
crepitations and/or wheeze.”9 
 It may occur in children upto 2-3 yrs however it is known to peak 
around 2-6 mnths.  There is involvement of lower respiratory tract within 
4-6 days after the onset of upper respiratory  tract infection  with 
appearance of clinical signs of cough, tachypnoea, hyperinflation, chest 
retractions, widespread crackles and wheezing.10 
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The differences in definition account  for the variability in study 
results so uniformity is essential to allow  comparison between studies 
which are performed in different parts of the world.11 
 
EPIDEMIOLOGY  
Acute bronchiolitis is still  the leading cause of hospitalization for  
infants younger than 1 year. Around >50% of all infants are infected with  
RSV in their first year of life and 22% develop symptomatic disease. 
Around 3% of all infants younger than one year are admitted to hospital 
with acute bronchiolitis.9 
 In the United States, around 700,000 infants are hospitalized  
each year with bronchiolitis, one-third of them require in-patient 
treatment, resulting in a calculated annual cost of approximately 500 
million dollars.  
Although bronchiolitis occurs mostly in the winter months 
November to March), it can occur year around.11 More than half of the 
patients of acute bronchiolitis  have recurrent  episodes of wheezing  till 
7-11 yrs of age. Pharmacological treatment of bronchiolitis is frequent 
practice, although no universal consensus  as to the efficacy or standard 
treatment exists.11  
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ETIOLOGY  
Acute bronchiolitis was initially thought to be complication of 
measles and mumps. 11Acute bronchiolitis is commonly caused by viral 
infection, with RSV accounting for 50%-80% of cases. Other  causes are 
adenovirus, parainfluenza viruses, influenza  virus, human 
metapneumovirus rhinovirus, human bocca virus, Chlamydia pneumonia 
and corona virus.RSV  is a single-stranded negative-sense,  RNA virus of 
the family Paramyxoviridae, subfamily Pneumoviridae. Two strains of 
the virus (A and B) and a large number of serotypes and genotypes have 
been identified as human pathogens. Among the acute bronchiolitis 
caused by the 2 strains, there is difference in outcome parameters such as 
length of hospital stay, intensive care admission and supplemental oxygen 
requirement.20 
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PATHOGENESIS 
 Acute bronchiolitis caused by RSV, results from infection and 
inflammation of  respiratory mucosa. Symptoms are a consequence of 
partial obstruction of distal airways. Histologic examination shows 
respiratory epithelial necrosis, monocytic inflammation with 
peribronchial oedema and distal airway obstruction with mucus and fibrin 
plugs. Infants are predisposed due to smaller distal airways and absence 
of active immunity against RSV and other viruses. 
Viral replication induces the production of inflammatory mediators 
by epithelial respiratory cells, contributing to the disease. Respiratory 
epithelial cell desquamation, mucosal oedema, and increased airway 
smooth muscle reactivity cause the respiratory symptoms. The 
relationship between disease severity and multiple virus co-infection is 
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not clear.10 The respiratory viruses cause inflammation and necrosis of 
the airway mucosa.  
The inflammation and necrosis of the airway exposes the irritant 
receptors, which, when stimulated by  deep breaths, cause coughing. To 
prevent coughing and reduce the work of breathing, infants and children 
breathe shallow and rapidly. Along with partial obstruction of small 
airways, this breathing pattern tends to trap a portion of each breath and 
leads to hyperinflation. Deep breaths are accompanied by rales  and 
expiratory wheezing and usually are followed by a paroxysm of 
coughing. Cyanosis may occur and be most marked during sleep when 
the drive to respiration is blunted. 
 Hypercapnia is a common feature  in infants who are less than one 
year of age, particularly when they are agitated or coughing. In addition 
to cough, stimulation of the irritant receptors also causes reflex 
constriction of the  larynx. Increased nasopharyngeal secretions can cause 
further upper airway  obstruction and increase the work of breathing.11  
CLINICAL FEATURES 
 Acute bronchiolitis occurs mainly in winter but can occur in other 
seasons. Parents report their children attend day-care centres or had 
contact with those who had cold symptoms. In the beginning of the 
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disease, children have rhinorrhoea and typically have cough along with 
poor feeding with a peak from 4-6 days of onset of illness. 
 Children with RSV causing acute bronchiolitis usually have fever 
of 38.50 C and that caused by other viruses have fever >39 0C. Infants 
with acute bronchiolitis have tachypnoea, mild to moderate hypoxia, and 
signs of respiratory distress, such as nasal flaring and respiratory muscle 
use. Physical examination reveals audible wheezing, crackles, rhonchi 
and prolonged expiration. Other findings are conjunctivitis and acute 
rhinitis. Abdominal distension might also be present due to pulmonary 
hyperinflation.10 
 CLINICAL SEVERITY SCORE 
 There are two clinical severity scoring systems that have been commonly 
used  for randomized trials involving infants with acute bronchiolitis. One 
is the Respiratory Distress Assessment Instrument (RDAI),and the other 
clinical severity score described by Wang et all 22, which assessess the 
respiratory rate, wheezing, retraction, general condition providing score 
of 10 to12. A clinical score of less than 4 is considered as mild disease, a 
score between 4 and 8 as moderate disease any score more than 9 as 
severe disease Respiratory distress assessment instrument (RDAI) 
provides a score ranging from 0 to 17, with a higher score indicating 
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more severe respiratory distress25. The components of the score as shown 
in the table below 
Table 1:RDAI SCORE 
 
0 1 2 3 4 Total 
Wheezing       
Expiration None End  1/2  ¾ All 4 
Inspiration None Part all - - 2 
Lung fields None <2/4 >3/4 - - 2 
Retractions       
Supraclavic
ular 
None Mild moderate marke
d 
- 3 
Intercostal None Mild moderate marke
d 
- 3 
Subcostal None Mild moderate marke
d 
- 3 
Total      17 
 
PROGNOSIS:  
Most children improve without any sequelae. The natural course of 
thedisease lasts for  7-10 days, however some children remain ill for 
weeks. Children predisposed to asthma may wheeze more when infected 
with RSV or exposed to allergic stimulus. 
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The mechanism of post-bronchiolitis wheezing is unknown, 
whether virus is the cause for persistant wheezing or wheezing is the 
consequence of airway disease.10  
INVESTIGATIONS  
Bronchiolitis is a clinical diagnosis.13 AAP does not support the use 
of diagnostic tests in the diagnosis of bronchiolitis.15 A mild leukocytosis 
with normal differential count may be present. Hypoxia is detected by 
pulse-oximetry or ABG analysis. CO2 retention may be seen in some 
infants. Pulse-oximetry is one of the most useful non invasive tools that 
can aid in treating a child with bronchiolitis. It can help in  assessing the 
degree of hypoxia as well as aid in evaluating the response of oxygen 
therapy.23 
Viruses from nasal samples can be detected by indirect fluorescent 
antibody detection, PCR, radioimmunoassay or direct culture. Virus 
diagnosing test may be used to link appropriate use of antibiotics. Chest 
X-ray may show hyperinflation, gross infiltrates which are migratory and 
attributable to postobstructive-atelectasis and peribronchial filling. When 
true alveolar infiltrates are seen secondary bacterial infection must  be 
suspected. Pleural effusion is rare.10 
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 MANAGEMENT  
The  history of acute bronchiolitis is  a self limiting disease that 
usually  lasts 7-10 days, and thus management is usually supportive.21,14 
Most of the  children with acute bronchiolitis will have a very mild 
disease and can  be  managed at home with supportive care from primary 
physician. Indications for hospitalisation include poor feeding, lethargy, 
history of apnoea, respiratory rate  >70/min, presence of nasal flaring 
and/or grunting, severe chest wall recession or oxygen saturation less 
than 94%.14 Care in the Paediatric ICU is advised for infants with 
hypoxemic respiratory failure (need for supplemental oxygen >40%), 
cyanosis, repeated episodes of prolonged apnoea, or respiratory and/or 
metabolic acidosis.25 
TREATMENT  
Treatment for acute bronchiolitis includes supportive care, Assisted 
feeding, minimal handling, gentle nasal suctioning and oxygen therapy.14 
are the most common forms of supportive care. 
OXYGEN THERAPY: 
 Adequate oxygenation is the main stay of therapy for Bronchiolitis.14 In 
the  UK, supplemental oxygen therapy is administered for oxygen 
saturation <95%, while AAP recommends its use only if oxygen 
saturations fall below 94% in previously healthy infants.14 O2 is given via 
nasal prongs and ensured SpO2  >94%. The significance of hypoxemia 
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with saturations below 95% as it relates to bronchiolitis outcomes has not 
been specifically studied and the thresholds  for administering 
supplemental oxygen vary widely.10  
HYDRATION THERAPY:  
Hydration is essential, oral/enteral fluids or when feedings is not 
tolerated, intravenous fluids. Fluids become important. Half of 
uncomplicated cases may require intravenous fluids. Careful monitoring 
mainly of the sick and high-risk children, is important, in order to prevent 
further complication.10 
BRONCHODILATORS:  
Bronchodilators are beta-2 agonists, adrenaline, ipratropium and 
theophylline. These are useful where bronchoconstriction contribute to 
wheezing. While beta-2 agonists were effective and reduced the need for 
intubation and mechanical ventilation, ipratropium was not as effective as 
beta -2 agonists. No studies have been conducted to evaluate the 
effectiveness of theophylline. It was found beta-2 agonists may increase 
mucosal blood flow, hence increase thickness and oedema and increase 
wheezing and respiratory distress, in addition excessive use may increase 
O2 consumption, further exacerbating respiratory failure.  
Adrenaline is likely to be more effective. It was found to reduce 
interstitial  oedema by its alpha agonistic activity and open small airways 
by its beta agonistic activity. A recent Cochrane review showed small 
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improvement in clinical scores but no change in hospitalisation. A large 
RCT and a Cochrane review concluded that there is insufficient evidence 
to support the use of adrenaline in inpatients with acute bronchiolitis; 
however, adrenaline may be preferred over salbutamol or placebo among 
outpatients, although admission rates were not significantly different.  
Inhaled bronchodilators are  used in the treatment of  acute 
bronchiolitis. Numerous clinical trials and systematic reviews examined 
the role of bronchodilators in the treatment of acute bronchiolitis. A 
recent meta-analysis of RCTs comparing bronchodilators with placebo in 
the treatment of acute bronchiolitis including 1428 infants concluded that 
bronchodilators  produce  short-term improvements in clinical scores but 
no significant improvement in oxygenation overall or in the rate of 
hospital admission.17However the AAP does not recommend the use of 
bronchodilators routinely in the management of acute bronchiolitis.15  
INHALED AND SYSTEMIC CORTICOSTEROIDS:  
Corticosteroids both inhaled and systemic neither produce any 
improvement in clinical scores nor decrease the length of hospital stay.17 
They are used for mild or moderate bronchiolitis treatment. Severely ill 
children who are receiving mechanical ventilation may be benefited but 
these do not prevent bronchospasm  following it. The anti-inflammatory 
effect of steroids may be useful.12,17 Systemic steroid therapy has no 
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immediate effect but inhaled steroids may be tried during the recovery 
period to reduce short term morbidity.24 
AEROSOLISED HUMAN DNAase : 
The use of aerosolised human DNAase was associated with 
improvement in chest X-ray score, but not much differences in RR, 
wheezing and retractions were seen when compared with control groups. 
Mucus in patients with bronchiolitis, cystic fibrosis, bronchiectasis was 
found to contain DNA.  
It increased the adhesiveness and viscosity of secretions. DNAase 
may also be useful in infections complicated by atelectasis, bronchial 
secretions and mucus  plugs. There was quick clinical improvement after 
2 hrs and radiologic  improvement after 24 hrs in children without cystic 
fibrosis and with bronchial secretions. 
ANTIVIRAL THERAPY 
Ribavirin is a broad-spectrum antiviral agent used in the treatment 
of RSV infection, and is the only antiviral drug that has been studied in 
children with acute viral bronchiolitis. Ribavirin inhibits the structural 
protein synthesis of the virus, reduces viral replication and 
immunoglobulin (IgE) E response.10 Its use, however, is controversial 
because of the questions about its efficacy, safety concerns, and its high 
cost. 
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Ribavirin may reduce the duration of mechanical ventilation and 
days of hospitalisation, and may decrease the incidence of  recurrent 
wheezing following bronchiolitis; however, in the absence of large  
RCTs, the effect of ribavirin remains unproven.17 Ribavirin, at present is 
not  recommended for use routinely in children with acute 
bronchiolitis.17,15,14  
The American Academy of Pediatrics has recommended the use of 
ribavirin in infants with congenital heart disease or chronic lung disease, 
impaired, multiple abnormalities, preterm infants and those less than 6 
weeks of age, and infants ventilated for RSV infection.30 
ANTIBIOTICS: 
 Antibiotics have no benefit in treating RSV but are important in 
treating secondary bacterial infection, such as streptococcus and 
staphylococcus.10. Antibiotics form mainstay of treatment when there is 
evidence of infection or sepsis. Sepsis is defined by the presence of 2 or 
more of the following-  
Temperature instability <35 or >38.50 C 
 Respiratory dysfunction  
Tachypnoea > 2 SD above the mean for age  
Hypoxemia (PaO2 < 70 mm Hg at room air)  
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Cardiac dysfunction 
 Tachycardia > 2 SD above the mean for age  
Delayed  capillary refill time > 3 sec 
Perfusion abnormalities 
Oliguria (urine output < 0.5 ml/kg/hr)  
Lactic acidosis (elevated plasma lactate and/or arterial pH 
<7.2) Altered mental status 
 Only one trial was included comparing antibiotics with placebo. It 
showed that antibiotics are no better than placebo in reducing the length 
of illness of bronchiolitis. Antibiotics need to be used cautiously owing to 
the side effects, cost to the patient and the community and increasing 
bacterial resistance to antibiotics.49  
 
LEUKOTRIENE RECEPTOR ANTAGONISTS:  
 Cysteinyl leukotrienes are significantly increased in respiratory 
secretions from infants with acute viral bronchiolitis and remain so at 
short-term follow-up, suggesting a possible role of these substances in the 
pathogenesis of the disease. An RCT compared montelukast, a specific 
cysteinyl leukotriene receptor antagonist, with placebo in infants with a 
first episode of bronchiolitis found that montelukast did not improve 
length of stay, clinical severity scores or cytokine levels in nasal lavage 
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fluid.17,12 AAP does not routinely recommend its use in the management 
of acute.15  
HELIOX: 
 The helium-oxygen mixture reduces the work of breathing and 
expiratory wheezing in children with obstructive disease. This therapy 
avoids respiratory failure and intubation. A case report by Paret and 
colleagues examined the use of heliox in a 4-month-old child with RSV 
bronchiolitis and impending respiratory failure. The administration of 
heliox (70% helium, 30% oxygen) averted the need for intubation and 
mechanical ventilation.10 Hollman et al further examined the effect of 
heliox in a randomized, double-blind, placebo-controlled study of patients 
admitted to a pediatric intensive care unit (PICU) with RSV bronchiolitis 
and showed that it eases respiratory distress in children with acute 
bronchiolitis. They also concluded that the combination of continuous 
positive upper airway pressure and heliox can reduce the need for 
intubation and mechanical ventilation.27 
HYPERTONIC SALINE:  
Airway oedema and mucus plugging are the predominant pathological 
features in acute bronchiolitis. Hypertonic saline decreases airway 
oedema, improves mucociliary clearance, and thus decreases airway 
obstruction.17 A recently published Cochrane Review of four trials 
involving 254 infants with acute bronchiolitis found that 3% saline results 
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in a significantly shorter length of hospital stay as well as a lower clinical 
score.26,12 While there is a lack of strong evidence to support the routine 
use of aerosolised hypertonic saline solution in children with acute viral 
bronchiolitis, minimal side effects and the limited cost of the treatment 
make this modality to deserve consideration for a large RCT.17  
RESPIRATORY PHYSIOTHERAPY: 
 The recommended treatment for children with bronchiolitis is 
based on positioning therapy, alveolar recruitement, expiration airflow 
increase using hand vibration and airway aspiration. Airway suctioning is 
an effective measure for tracheobronchial hygiene.  
Approximately 60% of respiratory resistance is in upper airways, 
hence clearance of these secretions may relieve the symptoms and reduce 
the work of breathing.10 
EXTRACORPOREAL MEMBRANE OXYGENATION:  
ECMO is used when severely ill children cannot be supported by 
conventional ventilation due to their ventilation and cardio-circulatory 
condition. Use of  ECMO for RSV is infrequent.10 In a study conducted 
by Flamant et al. out of 151 children 14 required ECMO with a mean 
duration of 12.1 days, with mechanical ventilation of 3.9 days before 
ECMO. The frequency of  BPD was significantly higher among these 
infants.29  
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INHALED NITRIC OXIDE: 
 Inhaled nitric oxide is used in those with severe hypoxemia and 
those who are refractory to ventilatory support. It is known to improve 
oxygenation and respiratory system resistance.10  
EXOGENOUS SURFACTANT: 
 Children infected with bronchiolitis by RSV have surfactant 
deficiency in both quantity and ability to decrease alveolar surface 
tension. Surfactant may have a role in maintaining the patency of small 
airways as well as on the lung compliance. But its clinical use remains 
infrequent.10  
CONVENTIONAL MECHANICAL VENTILATION: 
 Conventional mechanical ventilation in control-pressure 
ventilation mode is used for those children with obstructive or restrictive 
hypoxemia, however mixed mode (pressure regulated, volume controlled 
mode) can also be used.10 
HIGH-FREQUENCY OSCILLATION VENTILATION:  
High frequency mechanical ventilation is indicated in those with 
worsening condition, significant air leak, those with restrictive disease, 
with an oxygenation index >13. The main advantage is optimising 
ventilation and oxygenation with lower risk of pulmonary injury induced 
by mechanical ventilation.10  
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NONINVASIVE POSITIVE-PRESSURE VENTILATION:   
Noninvasive positive-pressure ventilation keeps airways open, 
improves respiratory flow, maintains functional residual capacity, 
improves pulmonary compliance, facilitates secretion mobilisation, 
reduces work of breathing, improves gas exchange and preserves 
surfactant synthesis and release. This therapy is used for those children 
with apnoeic episodes and hence prevents the use of invasive 
ventilation.10 
PROPHYLAXIS IMMUNOGLOBULINS AND MONOCLONAL 
ANTIBODIES:  
Palivizumab, a humanised monoclonal IgG1 antibody specifically 
directed to the RSV fusion protein, has been shown to be efficacious in 
preventing serious RSV disease in high risk patients.5 AAP recommends 
palivizumab prophylaxis to be given to selected infants and children with 
chronic lung disease or a history of prematurity (less than 35 weeks’ 
gestation) or with congenital heart disease.3 
 A recent Cochrane systematic review assessing immunoglobulin 
treatment of RSV infection rather than its role as a prophylactic measure 
identified four RCTs of which none demonstrated a statistically 
significant benefit.17 
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METHODOLOGY 
 
SOURCE OF DATA: 
Children in the age group of 2 months  to 2 years with bronchiolitis 
admitted in the Pediatrics ward, Government Mohan Kumaramangalam  
Medical College Hospital,salem. 
 
TYPE OF STUDY: 
Hospital based prospective interventional double  blinded 
randomized trial. 
 INCLUSION CRITERIA: 
 All cases of acute bronchiolitis with a Respiratory Distress 
Assessment Instrument (RDAI) score of 4 to 15 [on a scale of 0 (mild) to 
17 (severe)]. 
 EXCLUSION CRITERIA: 
The following children were excluded from the study-  
• Who received oral or inhaled corticosteroids during the preceding 2 
weeks Who have had a previous episode of wheezing  
• Who have a known chronic cardiopulmonary disease  
• Who are immunodeficient  
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• Who have had exposure to varicella within the preceding 3 weeks  
• Who present with severe respiratory distress ( pulse > 200/min, 
respiratory rate > 80/min, or RDAI score above 15 ) or profound 
lethargy/ altered sensorium . 
• Children who showed evidence of SIRS  or culture proven sepsis.  
• Who are preterms with corrected age of less than 4 weeks at 
presentation  
• Whose parents have not given consent 
METHODS OF COLLECTION OF DATA: 
The study was a hospital based prospective interventional  double 
blinded randomized trial .The  Study period was from july 2015 to june 
2016. Consent was taken from the parents of all the children included in 
the study. Random numbers were assigned by the statistician for all 
patients.The three drugs  were labelled  as A,B and C from the pharmacy   
and the drug was distributed to the patients as per the random number by 
the ward duty medical officer. The drugs were not disclosed to me till the 
end. 
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SAMPLE SIZE: 
 The study population was 90 .The  children who were absconded 
from ward, who went AMA and whose parents did not give consent were 
excluded from the study. 
DIAGNOSIS:  
Diagnosis of acute bronchiolitis  is mainly clinical, based on the 
presence of, nasal discharge, wheezy cough, fine inspiratory crackles 
and/or high pitched expiratory wheeze.  
• Cases were studied with reference to clinical history, physical 
findings, chest x-ray, total leucocyte count and differential count.  
• On admission, SpO2 was recorded in all patients.  
• RR, HR, axillary temperature and SpO2 were measured at 
admission and monitored initially half hourly for 2 hours, hourly 
for 4hours then every 6th houry.  
MONITORING:  
Monitoring was done by measuring the oxygen saturation with 
pulse-oximeter and the clinical status including the RDAI score, every 30 
min for the first 2 hours, every hourly for the next 4 hours and then every 
6th hourly during the hospital stay. However, based on the child’s 
condition the frequency of monitoring was increased if necessary.  
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INVESTIGATIONS:  
Total leucocyte count, differential count, chest x-ray, urine routine 
and urine culture and sensitivity were done in all patients. 
The following age specific values for heart rate, respiratory rate and 
leucocyte count were considered normal:      
 
TABLE 2:   AGE SPECIFIC VALUES 
  
AGE GROUP 
HEART 
RATE(BEATS /MIN) 
RESPIRATORY 
RATE(BEATS /MIN) 
0 day – 3 months 100-150 35-55 
3-6 months 90-120 30-45 
6-12 months 80-120 25-40 
1-2 year 70-110 20-30 
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TREATMENT: 
Supportive treatment like supplemental oxygen, intravenous fluids and 
antipyretics were given to all the children.  The study subjects were 
included into one of the 3 interventional groups through randomisation: 
 GROUP A: Given  nebulisation with drug A 
GROUP B:  Given  nebulisation with drug B 
  GROUP C: Given  nebulisation with drug C  
 
PROCEDURE 
The dosages of medications used were: 
• Nebulised adrenaline 3 ml in  1:1000 solution per treatment every 6 
th hourly  
• Nebulised salbutamol (0.15 mg /kg/dose) with 3 ml saline, per 
treatment every 6 th houly  
• Nebulised  budesonide 500 mcg in 3 ml saline per treatment every 
8th hourly 
The drugs A,B, C were not known till the end of the study. 
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RESULTS 
 
The study population was 90.Those  children who went 
AMA  who were absconded and whose parents  who have not 
given consent were excluded from the study. They were divided 
into 3 groups each of 30.Group A was given drug A , group B 
was given drug B and group C was given  drug C. Drugs A ,B 
and C  were not disclosed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
28 
 
1)AGE DISTRIBUTION   
TABLE 3:DISTRIBUTION OF CHILDREN ACCORDING TO 
AGE 
 
 
 
 
GRAPH 1:
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AGE DISTRIBUTION ACROSS THE 3 GROUPS
group 1 group2 group3
Group 
Age in months 
Total 2- 6 6 - 11  12-24 
N % N % N % 
Group A 14 47 13 43 3 10 30 
Group B 13 43 15 50 2 7 30 
Group C 13 43 14 47 3 10 30 
Total 40 44.4 42 46.7 8 8.9 90 
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In the above table, in group A , 14,(47%) of children were  between 
2-6 months,13,(43%) between 6-11 months  and 3(10%) between 12-24  
months.   In  group B ,13(43%) of children were between 2-6 months 
15(50%) between 6-12 months  and 2(7%) between 12-24 months.  In  
group C ,13(43%) of children were   2-6 months,14(47%) between 6-11 
months  and 3(10%) between 12-24 months. 
 
TABLE 4:MEAN AGE OF CHILDREN 
 
  Age   
Group N Mean SD ANOVA P 
Group A 30 6.27 3.79 
.026 0.974 Group B 30 5.73 3.25 
Group C 30 7.47 3.76 
Total 90 6.49 3.64 
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GRAPH 2:MEAN AGE OF CHILDREN 
 
  
In the above table, the mean age of presentation  in  Group A  was 
6 .27 months, in Group B was 5.73 months while in Group C it was 7.47 
months. There was no significant difference in the mean age of 
presentation between the 3 groups. (p=0.57 between Group 1 and 2, 
p=0.07  between Group 2 and 3, p=0.20 between Group 3 and 1) and the 
majority of cases were between 6-11 months. 
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GENDER DISTRIBUTION 
TABLE 5:DISTRIBUTION OF CHILDREN ACCORDING TO 
GENDER 
 Group 
Sex 
Total 
 
 
p value 
Male Female 
N % N % 
Group A 18 60 12 40 30 0.829 
Group B 20 67 10 33 30 
Group C 20 67 10 33 30 
Total 58 64 32 36 90 
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Out of 30 cases in Group A, 18 (60%) were males and 12 (40%) 
were females. In Group B, 20 (67%) were males and 10(33%) were 
females. In Group C, 20(67%) were males and 10(33%) were females. In 
total, there were 58 (64%) males and 32 (36%) were females. The 
difference in the proportion of males to females was not statistically 
significant. However, the ratio between males and female was 1.8. 
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TABLE 6:DURATION OF SYMPTOMS 
  Duration of symptoms (Days)   
 
N Mean SD ANOVA P 
Group A 30 4.67 2.50 
0.452 0.638 Group B 30 5.23 3.34 
Group C 30 5.27 2.29 
Total 90 5.06 2.73 
  
 
 
GRAPH  4: MEAN DURATION OF SYMPTOMS 
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In our study, Group A  had mean duration of symptoms of 4.6 
days, Group B had 5.23 days and Group C had 5.27 days. p value -0.6. 
Hence there was no significant difference between the 3 groups.  
The bar chart above shows the mean duration of symptoms which 
are highest for the Group C(5.27) followed by Group B(5.23) and Group 
A.(4.67).       p value is 0.638.Hence no significant decrease between the 
3 groups. 
 
 
 
 
 
 
 
  
35 
 
TABLE 7:CLINICAL FEATURES 
SYMPTOM/CLINICAL 
FEATURE 
No Yes 
Total 
N % N % 
Cold, Rhinorrhoea 29 32 61 68 90 
Cough 3 3 87 97 90 
Fever 25 28 65 72 90 
Wheeze 57 63 33 37 90 
Fast breathing 56 62 34 38 90 
Chest indrawing 73 81 17 19 90 
 
GRAPH  5: 
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In our study  cough was the most common presenting complaint 
seen in 87 (97%), followed by fever which was complained by 65 (72%), 
cold and rhinorrhoea in 61 (68%) and wheeze was present in 33 (37%). 
While fast breathing was present in 34 (38%), chest indrawing was 
present in 17 (19%) and feeding difficulty was seen in 7 (8%). 
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TABLE 8:RDAI SCORES (on admission)  
 
 
MEAN RDAI 
SCORING SD 
GROUP A 9.73 2.82 
GROUP B 9.77 2.39 
GROUP C 9.87 3.28 
 
GRAPH 6: 
BOX AND WHISKER PLOT
 Box and Whisker Plot of RDAI Scores of 3 Groups 
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The  table above shows the mean RDAI scores on admission for 
the three groups with mean RDAI scoring for group A being 9.73 and 
group B being 9.77 and group C being 9.87. The SDs  are 2.82,2.39,3.28 
respectively for the 3 groups 
In this study, after applying Mann-Whitney-U test when RDAI 
scores of Group A was compared to that of Group B, there was no 
significant difference between the two Groups (p=0.16). Similarly when 
Group B and Group C were compared, there was no significance 
(p=0.47). There was no significant difference between C and A as well 
(p=0.52).  
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TABLE 9: CHILDREN WIYH TACHYCARDIA (AT ADMISSION) 
 
 TACHYCARDIA 
NO 
TACHYCARDIA 
GROUP A 17(57) 13(43%) 
GROUP B 14(47%) 16(53%) 
GROUP C 17(57%) 13(43%) 
 
GRAPH 7: 
 
Among the children in group A, 17(57% )  of them had  
achycardia, in Group B 14( 47%)  of them had tachycardia and in group 
C 17(57%) of them had tachycardia. There was no significant difference 
between the groups (p value 0.61) 
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TABLE 10:  
MEAN HEART RATE OF CHILDREN IN THREE GROUPS 
 MEAN HR (/min) SD 
GROUP A 136 17 
GROUP B 138 26 
GROUP C 133 22 
 
GRAPH 8: 
 
 
The mean heart rate was  136  for Group A, 138  for Group B and  
133 for group C with a standard deviation of 26, 17 and 22 respectively. 
There was no significant difference between the groups (p value 0.61) 
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TABLE 11:CHILDREN WITH TACHYPNOEA 
 
 TACHYPNOEA(/MIN) NO TACHYPNOEA 
GROUP A 20(67%) 10(33%) 
GROUP B 14(47%) 16(53%) 
GROUP C 20(67%) 10(33%) 
TOTAL 54(60%) 36(40%) 
 
GRAPH 9: 
 
In the above table,in group A,20(67%) had tachypnoea,in group B 
14(47%) had tachypnoea, and in group C,20(67%) had tachypnoea.there 
was no significant difference among the groups. 
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TABLE 12)  MEAN RESPIRATORY RATE 
 
GRAPH 10: 
 
The mean respiratory rate for group A was 56.20., group B was 
50.87 and for group C 54.07. There was no significant difference between 
the 3 groups ( p value 0 .71) 
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TABLE 13: SPO2 IN CHILDREN AT ADMISSION 
 
In GroupA, 8 (27%) had SpO2 < 94%, other 22 (73%) maintained 
more than > 94%. Group B, 7 (23%) had SpO2 < 94%, 23 (77%) had 
SpO2 > 94%. In Group C, 4 (13%) had SpO2 < 94%, 26 (87%) 
maintained saturation at room air.There was no significant difference 
between the groups .p value 0.42 
  
 
Group 
SpO2-RA_Initial 
Total 
 Chi  
square 
p  Up to 94 Above 94 
N % N % 
Group A 8 27 22 73 30 
 1.73 0.42  Group B 7 23 23 77 30 
Group C 4 13 26 87 30 
Total 22 24 68 76 90     
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TABLE 14) Mean SPO2 among three groups 
 
 Mean SPO2 SD 
GROUP A 95.10 3.9 
GROUP B 94.40 5.76 
GROUP C 95.27 2.18 
 
GRAPH 11: 
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 From the above table the mean SPO2 in group A is 95.10 with a 
standard deviation of 3.9,  in group B the mean SPO2 is 94.40 with a 
standard deviation of 5.76 and the mean SPO2 in group C is 95.27 with a 
standard deviation of 2.18.  There is no significant difference between the 
mean SPO2 of the three groups at admission. 
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TABLE 15: CHILDREN WITH RETRACTIONS 
Group 
Retractions 
Total 
 Chi  
square 
p value  No Yes 
N % N % 
Group A 2 7 28 93 30 
1.07   0.585 Group B 3 10 27 90 30 
Group C 1 3 29 97 30 
Total 6 7 84 93 90     
 
GRAPH 12: 
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According to the above table, in Group A while 2 (7%) did not 
have retractions, all the remaining 28 (93%) did have retractions. In 
Group B, only 3 (10%) had no retractions, all the other 27(90%) had 
retractions. In Group C, 1 (3%) had no retractions whereas 29(907%)  had 
retractions.  p value was 0.585. The difference in the above proportion 
was not statistically significant. 
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TABLE 16: NUMBER OF CHILDREN WITH RHONCHI 
Group 
Rhonchi 
Total Yes No 
N % N % 
Group A 30 100  0 0  30 
Group B 30 100  0  0 30 
Group C 30 100 0   0 30 
Total 90 100  0  0 90 
 
In children with rhonchi, in Group A, all 30 (100%) had rhonchi, In 
Group B all 100% had some rhonchi. Also  in Group C,  all 30(100%) 
had rhonchi . 
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TABLE 17:  CHILDREN WITH HYPERINFLATION 
 
Group 
CXR 
Total 
 Chi  
square 
p  Hyperinflation 
No 
hyperinflation 
N % N % 
Group 
A 
27 90 3 10 30 
 1.73  0.421 
Group 
B 
27 90 3 10 30 
Group 
C 
24 80 6 20 30 
Total 78 87 12 13 90     
 
 
GRAPH  13   
 
 
 
 
0
5
10
15
20
25
30
GROUP A GROUP B GROUP C
HYPERINFLATION PRESENT
NO HYPERINFLATION
50 
 
 
 According to above table, 27 (90%) had hyperinflation on chest X-
ray, while 3 (10%) did not have. In group B, 27 (90%) had hyperinflation 
on chest X-ray and 3 (10%) did not have. In group C, 24  (80%) had 
hyperinflation and 6 (20%) did not have. P value is 0.421.Hence not 
statistically significant. 
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DURATION OF STAY AMONG THE GROUPS 
TABLE 18: 
 
MEAN NUMBER OF  
DAYS 
SD 
GROUP A 4.7 1.6 
GROUP B 4.9 3.1 
GROUP C 5.3 3.4 
 
GRAPH  14 
 
 
In our study, mean duration of stay in Group A was 4.7±1.6 days, 
in Group B, mean duration of stay of patients was 4.9 ± 3.1 days and 
Group C, mean duration was 5.3±3.4 days. There was no significant 
difference between the 3 groups.(P value 0.68) 
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OUTCOMES  
TABLE 19:MEAN VALUES AT ADMISSION 
 
 MEAN 
RDAI 
SD 
MEAN 
HR 
SD 
MEAN 
RR 
SD 
MEAN 
SPO2 
SD 
Group 
A 
9.73 2.82 135.53 17.2 56.20 11.96 95.10 3.9 
Group 
B 
9.77 2.39 138.16 25.7 50.87 14.46 94.40 5.76 
Group 
C 
9.87 3.28 133.80 21.7 54.07 11.93 95.27 2.18 
 
 
TABLE 20: 
OUTCOME AFTER 24 HRS OF ADMISSION 
 
MEA
N HR 
SD MEA
N RR 
SD 
MEA
N 
SPO2 
SD Mean 
RDAI 
SD 
GRO
UP A 129.23 18.86 45.67 
11.5
0 
96.93 2.05 6.9 2.51 
GRO
UP B 119.20 10.23 39.33 8.76 
95.77 4.68 5.3 1.69 
GRO
UP C 124.53 15.81 44.60 9.62 
96.8 1.54 6.2 2.83 
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In the above table ,after 24 hrs,in group A , the mean heart rate was 
129.23,the mean RR was 45.67 ,mean RDAI was 6.9 and  the mean spo2 
was 96.93. In group B the mean HR was 119.20,mean RR was 39.30 
,mean RDAI was 5.3 and mean spo2 was 96.93. In group C ,the mean HR 
was 124.53, mean RR was 44.60 ,mean RDAI was 6.2 and mean spo2 
was 96.8. 
 From the above table comparing the  outcomes after 24 hrs of 
admission  there is a decrease in  mean HR, mean RR, mean RDAI  and 
improvement in mean saturation. Among  all 3 groups and it is to be 
noted that marked improvement is shown in Group B in terms of all the 
four variables. 
TABLE 21: OUTCOME AFTER 72 HRS 
 
 MEAN 
HR SD 
MEAN 
RR SD 
MEAN 
SPO2 SD 
MEAN 
RDAI SD 
GROUP 
A 
117.57 6.70 38.00 10.43 97.27 2.75 
2.83 
 
2.98 
GROUP 
B 
117.37 10.96 36.17 5.65 97.37 2.65 1.10 1.45 
GROUP 
C 
123.20 12.19 41.50 8.27 97.1 2.78 2.30 2.97 
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In the above table , after 72 hrs ,in group A , the mean heart rate 
was 117.57 ,the mean RR was 38 ,mean RDAI was 2.83 and  the mean 
spo2 was 97.27. In group B the mean HR was 117.37.mean RR was 
36.17, mean RDAI was 1.45 and mean spo2 was 97.37.In group C ,the 
mean HR was 123.20, mean RR was 41.50 ,mean RDAI was 2.30 and 
mean spo2 was 97.1. 
From the above table comparing the  outcomes after 72 hrs of 
admission  the mean HR, mean RR,  and mean RDAI have shown 
improvement  in all 3 groups and it is to be noted that marked 
improvement is shown in Group B in terms of all the four variables. 
TABLE 22: 
COMPARISON BETWEEN ADMISSION AND 24 HOURS 
 
MEA
N HR 
AT 
ADM
ISSI
ON 
SD 
AFT
ER 24 
HRS 
SD 
M
EA
N 
RR 
SD 
AF
TE
R 
24 
HR
S 
SD 
M
E
A
N 
SP
O2 
S
D 
AF
TE
R 
24 
HR
S 
SD 
Group 
A 135.53 17.17 
129.2
3 
18.8
6 
56.2
0 
11.
96 
45.6
7 
11.
50 
95.
10 
1.
24 
96.9
3 2.05 
GRO
UP B 138.16 25.71 
119.2
0 10.23 
50.
87 
14.
46 
39.3
3 
8.7
6 
94.
.40 
1.
67 
95.7
7 4.68 
GRO
UP C 133.80 21.68 
124.5
3 15.81 
54.
07 
11.
93 
44.6
0 
9.6
2 
95.
27 
0.
91 96.8 1.54 
 
After applying t test to the above table at 24 hrs, there was  
significant difference between the groups with respect to means of HR, 
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RR ,RDAI and spo2 . There was significant reduction in HR,RR, RDAI  
and spo2  in group B when compared to group A and C 
TABLE 23: 
 COMPARISON BETWEEN ADMISSION AND 72 HOURS 
 
ME
AN 
HR 
SD 
AFT
ER 
72 
HRS 
SD 
ME
AN 
RR 
SD 
AFT
ER 
72 
HRS 
SD 
ME
AN 
SPO
2 
S
D 
AFT
ER 
72 
HRS 
S
D 
GRO
UP A 
135.5
3 
17.
17 
117.5
7 
6.7
0 
56.2
0 
11.
96 38.00 
10.
43 
95.1
0 
1.
24 97.27 
2.
75 
GRO
UP B 
138.1
6 
25.
71 
117.3
7 
10.
96 
50.8
7 
14.
46 36.17 
5.6
5 
94.4
0 
1.
67 97.37 
2.
65 
GRO
UP C 
133.8
0 
21.
68 
123.2
0 
12.
19 
54.0
7 
11.
93 41.50 
8.2
7 
95.2
7 
0.
91 97.1 
2.
78 
 
 After applying t test to the above table at 72 hrs, there is significant 
decrease in RDAI score  in group B in comparison to Groups A and C.(p 
=0.015) ,(p =0.011) ,(p=0.04). Similarly there is significant decrease in 
HR, and RR in group B in comparison with groups A and C.(p<0.05) 
Henceforth our study  has shown that there is statistical 
significance in the improvement in heart rate, respiratory rate, and  RDAI  
at 24 hrs  and 72 hrs in Group B in comparison with groups A and C 
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which has been depicted in the tables given below for individual 
variables.The improvement  in saturation is not significant at 72 hrs.The  
spo2 level has  increased in group B at 24 hrs and 72 hrs when compared 
to admission ,but statistically the difference is significant at 24 hrs but not 
in 72 hrs. 
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TABLE 24: 
COMPARISON TABLE FOR RDAI 
 
  
The RDAI of the 3 groups are compared at 24 hrs and 72 hrs using 
anova and was found  to have significant improvement and hence there 
was statistical difference. 
There is significant decrease in RDAI score  at 24 hrs and 72 hrs in 
group B in comparison to Group A.(p <0.05) 
  N Mean SD ANOVA P 
RDAI_Initial 
Group A 30 9.73 2.82 
0.018 0.982 
Group B 30 9.77 2.39 
Group C 30 9.87 3.28 
Total 90 9.79 2.82 
RDAI_24 hrs 
Group A 30 6.90 2.51 
3.114 
0.049 
   * 
Group B 30 5.37 1.69 
Group C 30 6.27 2.83 
Total 90 6.18 2.45 
RDAI_72 hrs 
Group A 30 2.83 2.98 
3.576 
0.032 
* 
Group B 30 1.10 1.45 
Group C 30 2.30 2.97 
Total 90 2.08 2.65 
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TABLE  25: 
COMPARISON TABLE OF HEART RATE 
  N Mean SD ANOVA P 
HR_Initial 
Group A 30 135.53 17.17 
0.31 0.738 
Group B 30 138.16 25.71 
Group C 30 133.80 21.68 
Total 90 135.83 21.63 
HR_24 hrs 
Group A 30 129.23 18.86 
3.19 0.046* 
Group B 30 119.20 10.23 
Group C 30 124.53 15.81 
Total 90 124.53 15.76 
HR_72 hrs 
Group A 30 117.57 6.70 
3.15 0.048* 
Group B 30 117.37 10.96 
Group C 30 123.20 12.19 
Total 90 119.38 10.47 
 
*Significant at 5 % 
There is significant Decrease in HR  at 24 hrs and 72 hrs in group B in 
comparison to Group A.(p <0.05) 
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TABLE 26: 
COMPARISON TABLE  OF RESPIRATORY RATE 
 
  N Mean SD ANOVA P 
RR_Initial 
Group A 30 56.20 11.96 
1.02 0.364 
Group B 30 50.87 14.46 
Group C 30 54.07 11.93 
Total 90 53.71 12.66 
RR_24 hrs 
Group A 30 45.67 11.50 
3.43 0.037* 
Group B 30 39.33 8.76 
Group C 30 44.60 9.62 
Total 90 43.20 10.29 
RR_72 hrs 
Group A 30 38.00 10.43 
3.16 0.047* 
Group B 30 36.17 5.65 
Group C 30 41.50 8.27 
Total 90 38.56 8.55 
 
Significant at 5%.The respiratory rates between the groups A 
,B,and  C were compared .There was marked  decrease in RR in group B 
when compared to group A  and group C.P  value (0.037) at 24 hrs and 
0.047 at 72 hrs. 
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TABLE  27: 
COMPARISON TABLE OF SPO2 
   N Mean SD ANOVA P 
SPO2_Initial 
Group A 30 95.10 3.91 
1.563 0.215 
Group B 30 94.40 5.76 
Group C 30 96.30 2.18 
Total 90 95.27 4.24 
 
 
 
 
SPO2_24 hrs 
Group A 30 96.43 2.14 
5.242 0.007* 
Group B 30 95.30 4.52 
Group C 30 97.77 1.07 
Total 90 96.50 3.09 
SPO2_72 hrs 
Group A 30 96.57 3.62 
1.964 0.146 
Group B 30 97.23 2.60 
Group C 30 97.93 1.26 
Total 90 97.24 2.70 
 
From this table it is evident that spo2 levels has shown 
improvement after 24 hrs and 72 hrs in groups A,B, C and in particular 
,there is statistical difference p value(<0.005), for mean spo2 level after 
24 hrs among the 3 groups. 
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TABLE 28: COMPARISON OF VARIABLES ACROSS THREE AGEGROUPS 
IN GROUP A 
  VARIABLE 
                      0 
TO 6 MONTHS 
                  6-12 
MONTHS 
                >= 
12 MONTHS 
P  
VALUE 
     
MEAN 
          
SD 
      
MEAN 
        
SD 
     
MEAN 
       
SD 
HR ADMISSION 137.5  17.54 134.53 17.50 130.67 19.21 0.803 
HR 24 HRS 133.143  21.01 128.07 17.59 116 6.92 0.257 
HR 72 HRS 118.929  6.67 117.38 7.08 112 1.1 0.273 
RR ADMISSION 59.0 10.77 53.38 14.10 53.33 4.1 0.487 
RR 24 HRS 45.286 9.56 45.84 12.99 46.66 17.47 0.981 
RR 72 HRS 36.429 9.15 37.38 6.70 48.0 24.33 0.285 
SPO2 ADMISSON 97.714 1.38 94.84 3.89 95.33 3.05 0.746 
 SPO2 24 HRS 96.643 2.40 97.53 1.39 95.66 2.51 0.287 
SPO2 72 HRS 96.286 3.86 97.76 1.16 97.33 1.15 0.665 
RDAIADMISSION 10.571 2.76 8.92 2.53 9.33 4.16 0.12 
RDAI 24 HRS 8.429 2.59 5.61 1.60 5.33 1.15 0.98 
RDAI  72 HRS 4.286 3.49 1.03 1.79 2.66 0.5 0.54 
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In the above table the four outcome variables   Heart rate, 
respiratory rate, spo2 and RDAI scores are compared within group A 
between three different age categories 0-6 months , 6-12 months and >= 
12 months. It is observed from the table that heart rate  has shown a 
decrease , the respiratory rate has reduced, the spo2 levels has increased 
and the RDAI scores has decreased when compared to admission levels  
at 24 hrs and 72 hrs for all  the three age groups. The table also shows 
that there is no statistical significance between the outcome variables 
among the the three age groups of Group A implying  that the action of 
the drug used in group A  is almost similar in action  in  all the three age 
groups. 
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TABLE 29: 
COMPARISON OF VARIABLES ACROSS THREE AGEGROUPS 
IN GROUP B 
  VARIABLE 
                      0 
TO 6 
MONTHS 
                  6-
12 MONTHS 
                >= 
12 MONTHS           P 
VALUE 
     
MEAN 
          
SD 
      
MEAN 
        
SD 
     
MEAN 
       
SD 
HR ADMISSION 142.6 25.53 137.8 26.31 112.0 5.65 0.302 
HR 24 HRS 122.0 11.32 115.2 6.73 131.1 15.55 0.064 
HR 72 HRS 118.7 5.51 118.6 13.76 103.2 4.24 0.158 
RR ADMISSION 46.23 8.85 53.66 15.59 70.25 14.14 0.062 
RR 24 HRS 37.38 6.60 40.13 10.29 46.35 8.48 0.396 
RR 72 HRS 37.23 5.74 34.33 5.21 43.15 1.14 0.079 
SPO2 ADMISSON 95.30 6.21 95.66 2.43 94.36 5.65 0.443 
 SPO2 24 HRS 94.23 4.27 96.26 5.32 97.58 0.70 0.888 
SPO2 72 HRS 97.61 1.70 97.0 3.40 98.50 0.74 0.664 
RDAIADMISSION 9.92 2.95 9.8 2.01 8.5 0.71 0.695 
RDAI 24 HRS 5.15 1.40 5.6 1.98 4.5 0.79 0.384 
RDAI  72 HRS 0.92 1.44 1.40 1.50 1.0 1.2 0.325 
 
In the above table the four outcome variables  Heart rate, 
respiratory rate, spo2 and RDAI scores are compared within group B 
between three different age categories 0-6 months , 6-12 months and >= 
12 months. It is observed from the table that the  mean heart rate has 
decreased, the respiratory rate has decreased, the spo2 levels  has 
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increased and the RDAI score has decreased when compared to 
admission levels and the levels at 24 hrs and 72 hrs for all  the three age 
groups. In comparison with the other groups ( group A and Group B), 
group B has shown marked improvement with regard to the outcome 
variables in the current study. The table also shows that there is no 
statistical significance between the outcome variables among the the three 
age groups of Group B implying  that the action of the drug used in 
Group B is almost similar in action in  all the three age groups. 
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TABLE 30: 
COMPARISON OF VARIABLES ACROSS THREE AGEGROUPS 
IN GROUP C 
  VARIABLE 
                      0 
TO 6 
MONTHS 
                  6-
12 MONTHS 
                >= 
12 MONTHS           P 
VALUE 
     
MEAN 
          
SD 
      
MEAN 
        
SD 
     
MEAN 
       
SD 
HR ADMISSION 142.6 25.53 137.8 26.31 112.0 5.65 0.302 
HR 24 HRS 122.0 11.32 115.2 6.73 131.1 15.55 0.064 
HR 72 HRS 118.7 5.51 118.6 13.76 103.2 4.24 0.158 
RR ADMISSION 46.23 8.85 53.66 15.59 70.25 14.14 0.062 
RR 24 HRS 37.38 6.60 40.13 10.29 46.35 8.48 0.396 
RR 72 HRS 37.23 5.74 34.33 5.21 43.15 1.14 0.079 
SPO2 ADMISSON 95.30 6.21 95.66 2.43 94.36 5.65 0.443 
 SPO2 24 HRS 94.23 4.27 96.26 5.32 97.58 0.70 0.888 
SPO2 72 HRS 97.61 1.70 97.0 3.40 98.50 0.74 0.664 
RDAIADMISSION 9.92 2.95 9.8 2.01 8.5 0.71 0.695 
RDAI 24 HRS 5.15 1.40 5.6 1.98 4.5 0.79 0.384 
RDAI  72 HRS 0.92 1.44 1.40 1.50 1.0 1.2 0.325 
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In the above table the four outcome variables ie Heart rate, 
respiratory rate, spo2 and RDAI scores are compared within group C 
between three different age categories 0-6 months , 6-12 months and >= 
12 months. It is observed from the table that  the  mean heart rate has 
decreased, the respiratory rate has reduced, the spo2 levels( saturation) 
has increased and the RDAI scores has decreased when compared to 
admission levels and the levels at 24 hrs and 72 hrs for all  the three age 
groups. The table also shows that there is no statistical significance 
between the outcome variables among the the three age groups of Group 
C implying  that the action of the drug used in group C  is almost similar 
in action  all the three age groups. 
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DISCUSSION 
AGE DISTRTIBUTION 
 The mean age of presentation in  Group A was 6.7 months while 
in Group B was 5 months. In  group C mean age of presentation was 7.6 
months.  This was comparable to other studies which showed peaking 
between 6-11 mnths.1 AAP showed peak time of presentation as 7 
months.26 
GENDER DISTRIBUTION 
In our study, out of 30 cases in Group A, 18 (60%) were males and 12 
(40%) were females. 
 In Group B, 20 (67%) were males and 10 (33%) were females.  
In Group 3, 20 (67%) were males and 10 (33%) were females. 
 In total, there were 58 (64%) males and 32 (36%) females. Male:female 
ratio was 1.8. This was similar to other studies which showed male 
preponderance.26  
MEAN DURATION OF SYMPTOMS 
In our study, Group A  had mean duration of symptoms of 4.9 
days, Group B  had 5.23 days and Group C had 5.27 days. P value-
0.638.there was no significant difference between the groups.This was 
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similar to other studies which showed mean duration of symptoms 
between 4-6 days .1,11  
Comparison of clinical symptoms with other studies: 
Symptoms Present study  Kabir et al Rasul CH et al 
Cough 87(97%) 100% 56% 
Cold 
/rhinorrhea 
61(68%) 100% NA 
Fast breathing 34(38%) NA NA 
Fever 65(72%) NA 46% 
Wheeze 33(37%) NA NA 
Chest  
indrawing 
17(19%) NA 100% 
 
The most common presenting complaint in our study was cough, 
which was present in 87 (97%) cases followed by fever in 65 (72%). This 
was followed by cold /rhinorrhoea which was present in 61(68%). 
Wheeze was present in 33(37%). This was followed by fast breathing in 
34 (38%). These observations were similar to other studies.52 except for 
chest indrawing which was present in only 17 (19%) in our study.  
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RDAI SCORES 
The mean RDAI score in group A was 9.73,in group B was 9.77 and in 
group C was 9.87. Our study showed  no significant difference in baseline 
RDAI scores between the Groups. After 24 hrs and 72 hrs ,there was 
significant reduction in the mean RDAI in all the 3 groups but the result 
was statistically significant in group B .p value 0.049 and 0.032 at 24 hrs 
and 72 hrs. 
CHILDREN WITH TACHYCARDIA 
 Among the children in group A, 57% (17)  of them had tachycardia, in 
Group B  47%(14%) of them had tachycardia and in group C  57%(17) of 
them had tachycardia. There was no significant difference between the 
groups (p value 0.61). After 24  hrs and 72 hrs ,there was significant 
reduction in the mean HR, in all the 3 groups but the  was statistically 
significant only  in group B. p value 0.046 and 0.048. 
CHILDREN WITH TACHYPNOEA 
 In the study, in group A, 20 (67%) had tachypnoea and 10 (33%) did not 
have. In Group B, 14 (47%) had tachypnoea, 16 (53%) did not have  
tachypnoea. In Group C, 20(67%) had tachypnoea and 10 (33%) did not 
have. 
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p value-0.71.There was no significant difference between the 3 groups. 
After 24 hrs and 72 hrs ,there was significant reduction in the mean RR, 
in all the 3 groups but that  was statistically significant only  in group B. p 
value 0.037 and 0.047 for 24 hrs and 72 hrs respectively. 
CHILDREN WITH SPO2<94%  
In Group A, 8 (27%) had SpO2 < 94%, other 22 (73%) maintained 
more than > 94%.In Group B, 7 (23%) had SpO2 < 94%, 23 (77%) had 
SpO2 > 94%. In Group C, 4 (13%) had SpO2 < 94%, 26 (87%) 
maintained saturation >94% at room air.There was  no significant 
baseline difference at admission.but after 24 hrs and there was 
improvement in saturation with significant difference in group B. p value 
0.007.but the difference was not statistically significant after 72 hrs. 
CHILDREN WITH RETRACTIONS 
According to the above table, in Group A while 2 (7%) did not 
have retractions, all the remaining 28 (93%) did have retractions. In 
Group B, only 3 (10%) had no retractions, all the other 27(90%) had 
retractions. In Group C, 1 (3%) had no retractions whereas 29(907%)  had 
retractions. . p value was 0.585. The difference in the above proportion 
was not statistically significant  
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CHILDREN WITH RHONCHI 
In children with rhonchi, in Group 1A all 30 (100%) had rhonchi, 
In Group B all 100% had some rhonchi. Also  in Group C,  all 30(100%) 
had rhonchi .In our study, rhonchi was most common sign in all the 3 
Groups, followed by tachypnoea and tachycardia. Retractions, 
crepitations and non-maintainance of saturation were present to lesser 
extent.All  these  findings correlated with the other studies like Rasul et 
al. 
CHILDREN WITH HYPERINFLATION 
 In our study,27 (90%) had hyperinflation on chest X-ray, in group 
A,while 3 (10%) did not have. In group B, 27 (90%) had hyperinflation 
on chest X-ray and 3 (10%) did not have. In group C, 25  (83.3%) had 
hyperinflation and 5 (16.6%) did not have. P value is 0.421.Hence not 
statistically significant. 
MEAN DURATION OF STAY  
In our study, mean duration of stay in Group A was 4.7±1.6 days, in 
Group B, mean duration of stay of patients was 4.9 ± 3.1 days and Group 
C, mean duration was 5.3±3.4 days. This was similar to the other studies 
conducted.13,26   . There was no significant difference between the 3 
groups.(P value 0.68)          
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   There is also  no statistical significance between the outcome variables 
among the the three age groups of Group A,B and C implying  that the 
action of the drugs  used in group A,B and C, respectively  is almost 
similar in action  in  all the three age groups. 
The outcome of this study was assessed at 24 and 72 hrs after 
administration of the drugs A ,B ,C . When assessed after 24 hrs there 
was significant reduction in HR, RR and RDAI in all groups but there 
was marked  improvement  in group B when compared to groups A and 
C. There was  improvement in saturation after 24 hrs in group B but that 
was not significant at 72 hrs. In Group B, there was decrease in 
tachypnoea,  tachycardia, improvement in RDAI  at 24 hrs and 72  
hrs.The significance was more in Group B compared to other Groups. 
So, overall there was significant decrease in HR, RR and RDAI in 
group B. There was clinical improvement in the children in group B and 
there was faster improvement and quick relief of symptoms .Hence, 
Group B showed significant improvement in decreasing tachycardia, 
tachypnoea and RDAI  but there was not much change in spo2 among 
any group.  
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Finally the groups A, B and C were revealed. Drug A was found to 
be SALBUTAMOL, drug B was ADRENALINE  and drug C was 
BUDESONIDE. There was no significant baseline difference between the 
Groups in terms of presence of tachypnoea,tachycardia,spo2 or RDAI 
scoring. After 24 hrs when the Groups were compared, there was 
significant reduction in HR, RR and ,RDAI  in Adrenaline Group 
compared to others. So this is  attributed to the effect of the drug B 
(ADRENALINE). Thus by all means, group B which is NEBULISED 
ADRENALINE brought about rapid symptomatic improvement 
compared to nebulised salbutamol and nebulised budesonide. Hence 
nebulised adrenaline can be initial choice for acute control of symptoms. 
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CONCLUSION 
 
• All the 3 groups reduced the respiratory distress and hence showed 
clinical improvement. However, Group B that is use of nebulised 
adrenaline brought about symptomatic improvement in the 
decrease in tachycardia, tachypnoea , RDAI score  and spo2 within 
24 hrs and the difference was significant.  
• Hence nebulised adrenaline can be the initial choice for acute 
control of symptoms 
• Use of nebulised adrenaline, nebulised  salbutamol and nebulised  
budesonide only however did not reduce the duration of stay in the 
hospital.  
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SUMMARY 
 Our study included a total of 90 cases, out of 30 cases in Group A, 
18(60%) were males and 12(40%) were females. In Group B, 20 (67%) 
were males and 10 (33%) were females. In Group C, 20 (67%) were 
females and 10(33%) were females. In total, there were 58 (64%) males 
and 32 (36%) were females. Male:female ratio was 1.8 The most 
common presenting complaint in our study was cough which was present 
in 87 (97%) cases followed by fever in 65 (72%). This was followed by 
cold/rhinorrhoea which was present in 61 (68%). Wheeze was present in  
33(37%), fast breathing was present in 34(38%). In our study, Group A 
had mean duration of symptoms of 4.7 days, Group B had 4 .9 days and 
Group C had 5.3 days. There was no significant difference between the 
three groups. There was improvement in all the 3 Groups after 24 hrs and 
after 72 hrs when compared to admission but there was significant 
reduction in HR,  RR ,RDAI ,and improvement in saturation after 24 hrs 
in Group  B, when compared to other Groups. This showed nebulised 
adrenaline brought about rapid symptomatic improvement in the 
condition. 
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LIMITATIONS  
Our study was a hospital based time bound study.  
The sample size was small.   
Follow-up of cases need to be done.  
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1 C Mahesha 3 months F edapadi 99260 5.11.15 8 days P P P P P P N N N 36.8 128
2 B Jeevandhi 6 months F Kondalampatti 25518 5.11.15 5 days p p p p p p N N N 36.6 171
3 C Mouliasa 11 months F Kalarampatty 26091 16.11.15 5 days p p p p p p N N N 38.7 168
4 C Padma 4 months F Krishnagiri 10170 17.11.15 3 days p p p p p N N N 38.2 162
5 B jayasree 2 months F Kannankuruchi 26167 17.11.15 8 days p p p p p N N N 37.8 156
6 C hariharan 11 months M settichavadi 26213 17.11.15 6 days p p p p p p N N N 37.6 156
7 A ruthran 12 months M Omalur 26751 19.11.15 7 days p p p N N N 39.2 110
8 B divyasree 2 months F Neikkarapatti 26547 23.11.15 2 days p p p N N N 36.8 126
9 B rithikshan 7months M Vazhapadi 26751 23.11.15 5 days p p p p N N N 38.5 130
10 A Nithish 3 months M Gajagayakanbati 27731 30.11.15 3 days p p p N N N 36.8 121
11 B Yadav 9 months M Nethimedu 27447 3.12.15 5 days p p p P N N N 37 112
12 C Cristina 4 months F Ayyodhiyapatnam 10645 3.12.15  6 days p p p N N N 37 140
13 A Varun 10 months M Periyaveeranam 28035 7.12.15 5 days p p N N N 36.5 142
14 B Sharmith 7 months M Chinnakoundapuram 27947 7.12.15 2 days p p N N N 37.6 160
C C B/o buvaneshwari 3 months M Valapadi 27956 7.12.15 4 days p p N N N 36.9 168
16 A Praveenkumar 2 months M Omalur 24989 7.12.15 4 days p p p N N N 36.7 164
17 B Yogeshwaran 2 months M Veeranam 28053 7.12.15 5 days p p p P N N N 37 142
18 C Tamilanbu 10 months M Nalapari 83462 12.12.15 10 days p p N N N 36.9 128
19 A Mugutnhan  7 months M Cuddalore 83630 15.12.15 3 days p p p N N N 37.4 160
20 B Akash 3 months M Kaliamman street 24645 18.12.15 5 days p p p P N N N 37.2 110
21 B Balaji 7 months M A.K Colony 25529 22.12.15 5 days p p p N N N 37 118
22 A Mukilan 2 months M Anathanapatti 55216 22.12.15 1 day p p N N N 37.4 132
23 B Yoga sree 3 months F Pichipalayam 85092 22.12.15 8 days p p p p N N N 37 136
24 B M.Mukilan 8 months M cudalore 83630 27.12.15 4 days p p N N N 36.8 110
25 A dhanush raja 10 months M Kalarampatty 95716 29.12.15 4 days p p N N N 37.3 128
26 B Rithik raja 3 months M Omalur 25279 29.12.15 15 days p p p p N N N 37 180
27 C harikrisnan 3 months M kondanayakampatti 25577 29.12.15 6 days p p N N N 38.5 112
28 A Sashwin 12 months M Valapadi 64031 2.2.16 7 days p P P N N N 37.6 134
29 C shyam 5 months M Karikdu 69701 5.2.16 8 days p p N N N 36.6 150
30 C Aradhana 14 months F Kichipalayam 80192 9.2.16 3 days p p N N N 37.7 128
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31 B Dhaniksha 12 months F Magudanchavadi 8628 12.2.16 5 days p p p N N N 36 116
32 B Gowtham 6 months M Dhadhagapati 10216 24.2.16 7 days p p loose stools N N N 37 132
33 A Amirtha nila 6 months F Karipatti 10244 19.2.16 4 days p p P P N N N 36.9 130
34 A Jessi 4 months F Sanyasikundu 10265 19.2.16 8 days p p P P N N N 366 130
35 B Samaya 4 months F kicchipalayam 11136 23.2.16 1 day p p P
Refusal of 
feed N N N 38.5 142
36 C Solomon 9 months M Jagirchinmapalayam 16774 18.3.16 9 days p p p N N N 39 128
37 A Athefa 7 months F Ammapet 16774 18.3.16 7 days p p p N N N 37 124
38 B Devendran 6 months M Idapadi 17794 22.3.16 1 day p p p p N N N 37 172
39 C Illavarsan 11 months M Gugai 19906 31.3.16 4 days p p p N N N 36.7 110
40 C Raman 2 months M Erumapalayam 23566 14.4.16 2 days p P P N N N 369 146
41 A Neha 7 months F Sanyasikundu 23639 14.4.16 15 days p p p vomiting N N N 37.4 178
39 B Illavarsan 11 months M Gugai 19906 31.3.16 4 days p p p N N N 36.7 110
43 A Illakkiya 18 months F Uthamasolapuram 24402 21.4.16 3 days p p p N N N 37.5 148
44 B lingesan 2 months M Kitchipalayam 26322 25.4.16 4days p p p N N N 38.8 198
45 C Rajesh 3months M
Thiruvakoundanoor 
byepass 27999 2.5.16 4 days p p p p N N N 37.8 142
46 A Inisha 6months F pallapatti 30085 9.5.16 4 days p p p p N N N 36.9 120
47 B Sreegokulan 4 months M Ammapet 30131 12.5.16 3 days p p p N N N 36.7 120
48 A Haswanth 6 months M Thirupathur 30158 12.5.16 6 days p loose stools N N N 36.7 135
49 A B/O Kanagavalli 5 months M vedathampatti 20200 17.5.16 3 days p p p N N N 36.7 129
50 B Yugesh 4 months M Sathyanagar 21209 17.5.16 5days p p p p N N N 37 110
51 C Roja 6months F Kichipalayam 30904 18.5.16 4 days p p P N N N 37.8 118
52 A Gomathi 9 months F Namakkal 31009 18.5.16 1 day p p p N N N 37.6 110
53 B Megatheswaran 8 months M Mettur 32726 23.5.16 3 days p p N N N 36.8 128
54 C kalikishore 4 months M Dhadhagapati 28388 26.5.16 4 days p p p N N N 36.9 110
55 A Kousalya 9 months F Omalur 26469 28.5.16 10 days p P P N N N 37.5 130
56 B Poornima 16 Months F kandhampatti 30331 28.5.16 1 day p p p N N N 37 108
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57 C Dhanuksha 11 months F Omalur 38884 29.5.16 3 days p p p Nasal block N N N 37.9 124
58 A Tamilarasi 3 months F Thattambatti 40437 2.6.16 8 days p p P P P N N N 36.8 128
59 B Kathirvel 6 months M Tiruchengodu 40463 12.6.16 5 days p p p P P P N N N 36.6 171
60 A Harini 6 months F Tammanaiakkampatti 38708 14.6.16 4 days p p p N N N 368 129
61 A Haridhar 4 months M kichipalayam 36550 16.6.16 3 days p p p P P N N N 38.2 162
62 B Madhan 3 months M Namakkal 40179 20.6.16  8 days p p P P N N N 37.8 156
63 C Alagesan 11 months M A D street 41127 20.6.16 4 days p p p P P P N N N 37.6 156
64 C Deepadharshan 12 months M Kondalampatti 42768 23.6.16 7 days p p p N N N 39.2 110
65 B Yukesh 7 months M Omalur 13643 23.6.16 2 days p P N N N 27.6 160
66 C Varshini 3 months F Muthmpati gate 42769 23.6.16 2 days p P N N N 36.9 168
67 A Krithikesh 3 months M Kichipalayam 42857 26.6.16 4 days p p p N N N 36.7 164
68 B Darshan 2 months M Vadapatti 44129 26.6.16 5 days p p P P N N N 37 142
69 A Poornima 6 months F kandhampatti 30331 30.6.16 6 days p loose stools N N N 36.7 135
70 A Srepriya 5 months M Pachapatti 24632 30.6.16 3 days p p P N N N 36.7 129
71 B Kavya 6 months F Kondalampatti 45518 1.07.16 5 days p p p p p p N N N 36.6 171
72 C Saicharan 11 months M settichavadi 46713 1.7.16 4 days p p p p p p N N N 37.6 156
73 C Kanisk 12 months M Omalur 48731 2.7.16 7 days p p p N N N 39.2 110
74 B Karthick 9 months M Nethimedu 46547 2.7.16 5 days p p p P N N N 37 112
75 C B/o Sundari 3 months M Valapadi 47856 4.7.16 7 days p p N N N 36.9 168
76 A Jeeva 2 months M Omalur 44989 4.7.16 4 days p p p N N N 36.7 164
77 B Saranya 3 months F Kichipalayam 45092 6.7.16 8 days p p p p N N N 37 136
78 B Hari 8 months M cudalore 43630 6.7.16 5 days p p N N N 36.8 110
79 A Sabari 2 months M Anathanapatti 45216 7.7.16 1 day p p N N N 37.4 132
80 C Akshya 4 months F kicchipalayam 41136 8.7.16 1 day p p P
Refusalof 
feed N N N 38.5 142
81 C Venkat 9 months M Jagirchinmapalayam 46774 8.7.16 9 days p p p N N N 39 98
82 A Gayathri 4 months F Sanyasikundu 40265 8.7.16 8 days p p P P N N N 366 130
83 A Shankar 4 months M Ammapet 40131 9.7.16 3 days p p p N N N 36.7 120
84 C Surendar 11 months M Gugai 49906 9.7.16 6 days p p p N N N 36.7 110
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85 C Saranya 9 months F Omalur 46469 10.7.16 10 days p P P N N N 37.5 130
86 A Dinesh 4 months M Ammapet 50131 11.7.16 3 days p p p N N N 36.7 120
84 C Surendar 11 months M Gugai 49906 9.7.16 6 days p p p N N N 36.7 110
88 A Vinoth 10 months M Kalarampatty 45716 12.7.16 4 days p p N N N 37.3 128
89 C srihari 4 months M Ammapet 40131 12.7.16 3 days p p p N N N 36.7 120
90 C priya 6months F Kichipalayam 40658 14.7.6 8 days p p P N N N 37.8 118
S.no Group Name Age Sex Address IP. No.
Date of 
admission
1 C Mahesha 3 months F edapadi 99260 5.11.15
2 B Jeevandhi 6 months F Kondalampatti 25518 5.11.15
3 C Mouliasa 11 months F Kalarampatty 26091 16.11.15
4 C Padma 4 months F Krishnagiri 10170 17.11.15
5 B jayasree 2 months F Kannankuruchi 26167 17.11.15
6 C hariharan 11 months M settichavadi 26213 17.11.15
7 A ruthran 12 months M Omalur 26751 19.11.15
8 B divyasree 2 months F Neikkarapatti 26547 23.11.15
9 B rithikshan 7months M Vazhapadi 26751 23.11.15
10 A Nithish 3 months M Gajagayakanbati 27731 30.11.15
11 B Yadav 9 months M Nethimedu 27447 3.12.15
12 C Cristina 4 months F Ayyodhiyapatnam 10645 3.12.15
13 A Varun 10 months M Periyaveeranam 28035 7.12.15
14 B Sharmith 7 months M Chinnakoundapuram 27947 7.12.15
C C B/o buvaneshwari 3 months M Valapadi 27956 7.12.15
16 A Praveenkumar 2 months M Omalur 24989 7.12.15
17 B Yogeshwaran 2 months M Veeranam 28053 7.12.15
18 C Tamilanbu 10 months M Nalapari 83462 12.12.15
19 A Mugutnhan  7 months M Cuddalore 83630 15.12.15
20 B Akash 3 months M Kaliamman street 24645 18.12.15
21 B Balaji 7 months M A.K Colony 25529 22.12.15
22 A Mukilan 2 months M Anathanapatti 55216 22.12.15
23 B Yoga sree 3 months F Pichipalayam 85092 22.12.15
24 B M.Mukilan 8 months M cudalore 83630 27.12.15
25 A dhanush raja 10 months M Kalarampatty 95716 29.12.15
26 B Rithik raja 3 months M Omalur 25279 29.12.15
27 C harikrisnan 3 months M kondanayakampatti 25577 29.12.15
28 A Sashwin 12 months M Valapadi 64031 2.2.16
29 C shyam 5 months M Karikdu 69701 5.2.16
30 C Aradhana 14 months F Kichipalayam 80192 9.2.16
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162 110 58 54 48 99 96 96 96 7 2 0 Y,scr,icr P 10.2 9600
112 118 42 44 30 98 93 98 98 12 9 4 Y,scr,icr P 8.7 17800
110 112 66 58 54 98 93 97 93 14 4 0 Y,scr,icr P 10.2 13800
128 120 36 36 36 96 80 96 84 14 14 13 Y,scr,icr P 10.6 12200
134 120 40 38 36 98 96 96 96 12 7 3 Y,scr,icr P 10.2 9000
118 118 72 38 50 99 96 96 97 13 9 0 Y,scr,icr P 9.8 9700
112 112 60 66 76 98 96 93 96 6 4 2 Y,scr,icr P 9.2 11400
128 122 34 38 44 98 94 96 96 9 5 0 Y,scr,icr P 11.5 14400
110 122 80 52 44 99 98 99 99 10 6 2 Y,scr,icr P 11 5600
140 115 64 36 24 99 98 99 99 10 5 0 Y,scr,icr P 9.7 8600
130 100 64 20 30 98 98 97 98 8 3 0 Y,scr,icr P 10.5 11400
150 115 62 40 56 96 96 96 97 14 9 4 Y,scr,icr P 11 10660
124 112 52 48 42 96 88 96 96 7 7 3 Y,scr,icr p 9.2 12700
122 126 36 32 30 98 92 98 98 11 7 3 Y,scr,icr P 11.5 9000
118 148 56 38 40 98 95 98 98 12 6 3 Y,scr,icr P 11.6 7000
162 123 36 58 33 96 92 93 97 13 8 5 Y,scr,icr P 11.1 9800
112 122 38 34 32 90 98 85 94 10 6 0 Y,scr,icr P 9.7 11700
150 112 42 34 35 98 98 99 99 10 10 0 Y,scr,icr P 9.8 13000
110 126 44 36 28 97 94 97 98 7 4 0 Y,scr,icr P 11.2 9800
125 106 56 36 30 98 97 97 98 9 3 0 Y,scr,icr P 11.5 12500
110 100 50 44 32 97 96 98 99 9 5 2 Y,scr,icr P 9.8 13400
128 116 66 40 35 97 96 96 97 14 10 8 Y,scr,icr P 7.2 7900
140 120 60 28 32 98 98 90 98 14 5 0 Y,scr,icr P 10 7400
110 108 42 48 38 98 98 99 98 12 6 0 N P 7.8 8900
118 128 64 52 44 97 96 97 97 7 6 0 Y,scr,icr P 10 13200
110 112 48 30 40 98 97 98 99 7 5 3 N P 11.4 17000
150 112 34 32 32 98 97 97 98 7 3 0 Y,scr,icr P 11.2 12000
124 112 54 32 36 98 98 96 98 8 6 3 N P 9.8 11700
120 154 60 60 48 98 92 97 97 8 7 2 N P 10.1 12200
114 115 60 56 48 99 99 99 98 13 10 4 Y,scr,icr P 11.9 11400
S.no Group Name Age Sex Address IP. No.
Date of 
admission
31 B Dhaniksha 12 months F Magudanchavadi 8628 12.2.16
32 B Gowtham 6 months M Dhadhagapati 10216 24.2.16
33 A Amirtha nila 6 months F Karipatti 10244 19.2.16
34 A Jessi 4 months F Sanyasikundu 10265 19.2.16
35 B Samaya 4 months F kicchipalayam 11136 23.2.16
36 C Solomon 9 months M Jagirchinmapalayam 16774 18.3.16
37 A Athefa 7 months F Ammapet 16774 18.3.16
38 B Devendran 6 months M Idapadi 17794 22.3.16
39 C Illavarsan 11 months M Gugai 19906 31.3.16
40 C Raman 2 months M Erumapalayam 23566 14.4.16
41 A Neha 7 months F Sanyasikundu 23639 14.4.16
39 B Illavarsan 11 months M Gugai 19906 31.3.16
43 A Illakkiya 18 months F Uthamasolapuram 24402 21.4.16
44 B lingesan 2 months M Kitchipalayam 26322 25.4.16
45 C Rajesh 3months M
Thiruvakoundanoor 
byepass 27999 2.5.16
46 A Inisha 6months F pallapatti 30085 9.5.16
47 B Sreegokulan 4 months M Ammapet 30131 12.5.16
48 A Haswanth 6 months M Thirupathur 30158 12.5.16
49 A B/O Kanagavalli 5 months M vedathampatti 20200 17.5.16
50 B Yugesh 4 months M Sathyanagar 21209 17.5.16
51 C Roja 6months F Kichipalayam 30904 18.5.16
52 A Gomathi 9 months F Namakkal 31009 18.5.16
53 B Megatheswaran 8 months M Mettur 32726 23.5.16
54 C kalikishore 4 months M Dhadhagapati 28388 26.5.16
55 A Kousalya 9 months F Omalur 26469 28.5.16
56 B Poornima 16 Months F kandhampatti 30331 28.5.16
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142 106 60 40 42 98 98 98 99 9 4 0 Y,scr,icr P 9.6 6540
124 122 64 60 30 98 98 92 97 7 6 0 Y,scr,icr P 8.9 10200
115 118 42 36 28 98 97 98 98 8 5 0 N P 10 9400
116 118 68 54 50 99 96 99 100 8 6 3 Y,scr,icr P 12 9000
138 120 43 36 42 95 75 94 98 14 5 0 Y,scr,icr P 11.2 12000
140 120 48 40 44 98 97 98 98 14 8 5 Y,scr,icr P 9.1 12000
110 118 30 30 32 99 99 96 98 8 6 0 Y,scr,icr P 11.1 7800
110 118 40 36 32 99 95 98 85 10 5 0 Y,scr,icr P 10.3 15600
128 122 50 54 36 98 98 97 99 14 6 0 Y,scr,icr P 11.6 13000
118 122 50 54 36 98 98 97 99 5 6 0 Y,scr,icr P 9.3 6890
160 122 62 60 42 96 92 99 99 13 4 5 Y,scr,icr P 11.7 18800
115 142 60 38 35 99 97 78 97 11 8 2 Y,scr,icr P 11.6 13000
112 112 52 42 32 98 92 98 98 14 6 3 Y,scr,icr P 10.9 12300
120 118 36 40 40 99 98 100 100 7 3 0 Y,scr,icr P 8.6 9200
110 122 44 36 32 98 95 96 96 10 7 7 Y,scr,icr P 10.5 10900
150 118 48 42 36 98 94 95 96 9 8 0 Y,scr,icr P 10.8 13300
114 114 58 54 48 98 97 96 98 8 5 3 Y,scr,icr P 9.8 10700
118 110 58 54 40 98 90 99 98 13 4 3 Y,scr,icr P 11.2 8900
150 128 46 42 35 99 97 99 98 8 9 2 Y,scr,icr P 9.8 10400
106 114 56 44 38 99 97 96 98 6 4 0 Y,scr,icr P 10 10300
118 130 64 60 56 99 97 98 98 9 2 0 Y,scr,icr P 11.2 7800
148 118 78 66 50 98 98 97 99 6 5 0 Y,scr,icr P 11.2 10300
111 142 36 36 32 98 96 97 98 8 3 0 Y,scr,icr P 10 18200
150 118 34 30 32 98 96 98 97 11 3 0 Y,scr,icr P 7 11300
122 108 62 44 42 100 100 99 97 10 9 3 Y,scr,icr P 11.7 11900
120 100 80 52 44 98 90 97 98 8 5 0 Y,scr,icr P 11.5 10800
S.no Group Name Age Sex Address IP. No.
Date of 
admission
57 C Dhanuksha 11 months F Omalur 38884 29.5.16
58 A Tamilarasi 3 months F Thattambatti 40437 2.6.16
59 B Kathirvel 6 months M Tiruchengodu 40463 12.6.16
60 A Harini 6 months F Tammanaiakkampatti 38708 14.6.16
61 A Haridhar 4 months M kichipalayam 36550 16.6.16
62 B Madhan 3 months M Namakkal 40179 20.6.16
63 C Alagesan 11 months M A D street 41127 20.6.16
64 C Deepadharshan 12 months M Kondalampatti 42768 23.6.16
65 B Yukesh 7 months M Omalur 13643 23.6.16
66 C Varshini 3 months F Muthmpati gate 42769 23.6.16
67 A Krithikesh 3 months M Kichipalayam 42857 26.6.16
68 B Darshan 2 months M Vadapatti 44129 26.6.16
69 A Poornima 6 months F kandhampatti 30331 30.6.16
70 A Srepriya 5 months M Pachapatti 24632 30.6.16
71 B Kavya 6 months F Kondalampatti 45518 1.07.16
72 C Saicharan 11 months M settichavadi 46713 1.7.16
73 C Kanisk 12 months M Omalur 48731 2.7.16
74 B Karthick 9 months M Nethimedu 46547 2.7.16
75 C B/o Sundari 3 months M Valapadi 47856 4.7.16
76 A Jeeva 2 months M Omalur 44989 4.7.16
77 B Saranya 3 months F Kichipalayam 45092 6.7.16
78 B Hari 8 months M cudalore 43630 6.7.16
79 A Sabari 2 months M Anathanapatti 45216 7.7.16
80 C Akshya 4 months F kicchipalayam 41136 8.7.16
81 C Venkat 9 months M Jagirchinmapalayam 46774 8.7.16
82 A Gayathri 4 months F Sanyasikundu 40265 8.7.16
83 A Shankar 4 months M Ammapet 40131 9.7.16
84 C Surendar 11 months M Gugai 49906 9.7.16
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148 118 36 32 30 98 96 99 99 8 5 3 Y,scr,icr P 10 12300
148 110 70 42 40 98 96 96 96 7 5 0 Y,scr,icr P 10.2 9600
121 122 43 36 42 99 93 98 96 12 7 2 Y,scr,icr P 8.7 13600
110 110 64 32 32 99 99 99 100 8 6 0 Y,scr,icr P 9.1 11900
110 126 64 50 46 96 96 96 84 14 14 13 Y,scr,icr P 10.6 18000
118 121 40 36 32 98 96 96 96 12 8 3 Y,scr,icr P 10.2 9000
110 118 72 38 50 99 96 96 97 13 9 0 Y,scr,icr P 9.8 9700
114 112 42 44 30 98 96 93 96 6 4 2 Y,scr,icr P 9.2 11400
110 130 80 52 44 98 92 98 98 11 6 2 Y,scr,icr P 11.5 9000
130 148 56 38 40 98 95 98 98 10 8 3 Y,scr,icr P 11.6 7000
114 124 48 36 32 96 92 93 97 13 9 5 Y,scr,icr P 11.1 9800
111 118 44 32 30 99 98 100 100 7 5 0 Y,scr,icr P 9.7 10700
148 110 60 66 38 96 90 99 98 13 4 3 Y,scr,icr P 11.2 8900
110 118 64 36 24 98 97 99 98 8 9 2 Y,scr,icr p 9.8 10400
122 124 60 28 32 98 93 98 98 12 8 4 Y,scr,icr P 8.7 17800
122 118 72 38 50 99 96 96 97 5 3 0 Y,scr,icr P 9.8 9700
110 112 42 44 40 98 96 93 96 6 4 2 Y,scr,icr P 9.2 11400
112 100 70 42 32 98 98 97 98 8 3 0 Y,scr,icr P 10.5 11400
115 148 56 38 40 98 95 98 98 10 6 3 Y,scr,icr P 11.6 7000
132 123 66 40 35 96 92 93 97 13 10 5 Y,scr,icr P 11.1 9800
130 128 48 40 40 98 98 90 98 14 6 0 Y,scr,icr P 10 7400
109 106 38 34 32 98 98 99 98 6 3 0 N P 7.8 8900
168 128 62 44 42 97 96 96 97 14 12 8 Y,scr,icr P 7.2 7900
110 132 58 54 40 95 75 94 98 14 5 7 Y,scr,icr P 11.2 12000
110 120 48 40 44 98 97 98 98 14 8 5 Y,scr,icr P 9.1 12000
118 118 60 66 42 99 96 99 100 8 6 3 Y,scr,icr P 12 9000
110 110 44 36 22 98 97 96 98 8 8 3 Y,scr,icr P 9.8 10700
115 122 50 54 36 98 98 97 99 5 6 0 Y,scr,icr P 11.6 13000
S.no Group Name Age Sex Address IP. No.
Date of 
admission
85 C Saranya 9 months F Omalur 46469 10.7.16
86 A Dinesh 4 months M Ammapet 50131 11.7.16
84 C Surendar 11 months M Gugai 49906 9.7.16
88 A Vinoth 10 months M Kalarampatty 45716 12.7.16
89 C srihari 4 months M Ammapet 40131 12.7.16
90 C priya 6months F Kichipalayam 40658 14.7.6
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110 122 50 54 36 98 98 97 99 5 6 0 Y,scr,icr P 11.7 11900
158 108 68 54 50 100 100 99 97 10 7 3 Y,scr,icr P 9.8 10700
132 132 70 42 32 98 97 96 98 8 8 3 Y,scr,icr P 11.6 13000
132 128 30 30 32 97 96 97 97 7 5 0 Y,scr,icr P 10 13200
115 132 70 42 38 98 97 96 98 8 8 3 Y,scr,icr P 9.8 10700
111 112 64 60 56 99 97 98 98 9 2 0 Y,scr,icr P 11.2 7800
S.no Group Name Age Sex Address IP. No.
Date of 
admission
1 C Mahesha 3 months F edapadi 99260 5.11.15
2 B Jeevandhi 6 months F Kondalampatti 25518 5.11.15
3 C Mouliasa 11 months F Kalarampatty 26091 16.11.15
4 C Padma 4 months F Krishnagiri 10170 17.11.15
5 B jayasree 2 months F Kannankuruchi 26167 17.11.15
6 C hariharan 11 months M settichavadi 26213 17.11.15
7 A ruthran 12 months M Omalur 26751 19.11.15
8 B divyasree 2 months F Neikkarapatti 26547 23.11.15
9 B rithikshan 7months M Vazhapadi 26751 23.11.15
10 A Nithish 3 months M Gajagayakanbati 27731 30.11.15
11 B Yadav 9 months M Nethimedu 27447 3.12.15
12 C Cristina 4 months F Ayyodhiyapatnam 10645 3.12.15
13 A Varun 10 months M Periyaveeranam 28035 7.12.15
14 B Sharmith 7 months M Chinnakoundapuram 27947 7.12.15
C C B/o buvaneshwari 3 months M Valapadi 27956 7.12.15
16 A Praveenkumar 2 months M Omalur 24989 7.12.15
17 B Yogeshwaran 2 months M Veeranam 28053 7.12.15
18 C Tamilanbu 10 months M Nalapari 83462 12.12.15
19 A Mugutnhan  7 months M Cuddalore 83630 15.12.15
20 B Akash 3 months M Kaliamman street 24645 18.12.15
21 B Balaji 7 months M A.K Colony 25529 22.12.15
22 A Mukilan 2 months M Anathanapatti 55216 22.12.15
23 B Yoga sree 3 months F Pichipalayam 85092 22.12.15
24 B M.Mukilan 8 months M cudalore 83630 27.12.15
25 A dhanush raja 10 months M Kalarampatty 95716 29.12.15
26 B Rithik raja 3 months M Omalur 25279 29.12.15
27 C harikrisnan 3 months M kondanayakampatti 25577 29.12.15
28 A Sashwin 12 months M Valapadi 64031 2.2.16
29 C shyam 5 months M Karikdu 69701 5.2.16
30 C Aradhana 14 months F Kichipalayam 80192 9.2.16
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P64,L40,E2 Hyperinflated NAD NAD NAD 4 Days 4 days N
P55,L40,E3 Hyperinflated NAD NAD NAD 6 days 6 days N
P80,L15,E2
Hyperinflated with 
pneumonic patch NAD NAD NAD 2 days 3 days N
P72,L19,E5 Patch in right upper lobe NAD NAD NAD 6 days 6 days N
P55,L40,E3 Hyperinflated NAD NAD NAD 5 days 5 days N
P35,L60,E3 Hyperinflated NAD NAD NAD 3 days 3 days N
P48,L45,E3 Hyperinflated NAD NAD NAD 6 days 8 days N
P49,L49,E1 Hyperinflated NAD NAD NAD 6 days 7 days N
P55,L40,E3 Hyperinflated NAD NAD NAD 7 days 7 days N
P25,L65,E4 Hyperinflated NAD NAD NAD 3 days 3 days N
P20,L71,E6 Hyperinflated NAD NAD NAD 3 days 3 days N
P40,L53,E2 Hyperinflated NAD NAD NAD 6 days 7 days N
P40L58E1 Hyperinflated NAD NAD NAD 6 days 6 days N
P70L26E2 Hyperinflated NAD NAD NAD 6 days 6 days N
P38L61E1 Hyperinflated NAD NAD NAD 6 days 6 days N
P35,L60,E3 Hyperinflated NAD NAD NAD 6 days 6 days N
P35,L60,E2 Hyperinflated NAD NAD NAD 5 days 5 days N
P20,L72,E6 Hyperinflated 3-5 Pus cells NAD NAD 5 days 5 Days N
P35,L60,E3 Hyperinflated NAD NAD NAD 4 Days 4 days N
P27,L72,E3
Pneumonic patch in R 
upper lung field NAD NAD NAD 6 days 6 days N
P45,L45,E3 Hyperinflated NAD NAD NAD 3 Days 3 days N
P50,L45,E3 Hyperinflated NAD NAD NAD 6 days 6 days N
P40,L54,E2 Hyperinflated NAD NAD NAD 3 days 3 days N
P72,L19,E5 Hyperinflated NAD NAD NAD 5 days 5 days N
P10,L81,E6 Hyperinflated NAD NAD NAD 4 Days 4 days N
P45,L50,E4 Hyperinflated NAD NAD NAD 5 days 5 days N
P37,L58,E3 Hyperinflated NAD NAD NAD 3 days 3 days N
P32,L30,E6 Hyperinflated NAD NAD NAD 3 days 3 days N
P43,L42,E2 Hyperinflated NAD NAD NAD 3 days 3days N
P60,L35,E3 Pnneumonic patch NAD NAD NAD 5 days 5 days N
S.no Group Name Age Sex Address IP. No.
Date of 
admission
31 B Dhaniksha 12 months F Magudanchavadi 8628 12.2.16
32 B Gowtham 6 months M Dhadhagapati 10216 24.2.16
33 A Amirtha nila 6 months F Karipatti 10244 19.2.16
34 A Jessi 4 months F Sanyasikundu 10265 19.2.16
35 B Samaya 4 months F kicchipalayam 11136 23.2.16
36 C Solomon 9 months M Jagirchinmapalayam 16774 18.3.16
37 A Athefa 7 months F Ammapet 16774 18.3.16
38 B Devendran 6 months M Idapadi 17794 22.3.16
39 C Illavarsan 11 months M Gugai 19906 31.3.16
40 C Raman 2 months M Erumapalayam 23566 14.4.16
41 A Neha 7 months F Sanyasikundu 23639 14.4.16
39 B Illavarsan 11 months M Gugai 19906 31.3.16
43 A Illakkiya 18 months F Uthamasolapuram 24402 21.4.16
44 B lingesan 2 months M Kitchipalayam 26322 25.4.16
45 C Rajesh 3months M
Thiruvakoundanoor 
byepass 27999 2.5.16
46 A Inisha 6months F pallapatti 30085 9.5.16
47 B Sreegokulan 4 months M Ammapet 30131 12.5.16
48 A Haswanth 6 months M Thirupathur 30158 12.5.16
49 A B/O Kanagavalli 5 months M vedathampatti 20200 17.5.16
50 B Yugesh 4 months M Sathyanagar 21209 17.5.16
51 C Roja 6months F Kichipalayam 30904 18.5.16
52 A Gomathi 9 months F Namakkal 31009 18.5.16
53 B Megatheswaran 8 months M Mettur 32726 23.5.16
54 C kalikishore 4 months M Dhadhagapati 28388 26.5.16
55 A Kousalya 9 months F Omalur 26469 28.5.16
56 B Poornima 16 Months F kandhampatti 30331 28.5.16
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P60,L45,E3 Hyperinflated NAD NAD NAD 4 Days 4 days N
P23,L67,E6 Hyperinflated NAD NAD NAD 3 days 3 days N
P40,L56,E2 Hyperinflated NAD NAD NAD 3 days 3 days N
P14,L74,E10 Hyperinflated NAD NAD NAD 5 days 5 days N
P80,L15,E4
Pneumonic patch in R 
upper lung field NAD NAD NAD 11 Days 11 days N
P20,L73,E5
Pneumonic patch in L 
upper lung field NAD NAD NAD 3 days 4 days N
P50,L46,E3 Hyperinflated NAD NAD NAD 3 days 3 days N
P32,l60,E6 Hyperinflated NAD NAD NAD 4 Days 4 days N
P36,L60,E4 Hyperinflated NAD NAD NAD 3 days 3 days N
P25,L65,E4 Hyperinflated NAD NAD NAD 3 days 3 days N
p68,L28,E2 Hyperinflated NAD NAD NAD 6 days 7 days N
P36,L60,E4 Hyperinflated NAD NAD NAD 3 days 3 days N
P80L15E3
Pneumonic patch in R 
upper lung field NAD NAD NAD 4 days 4 days N
P20L76E2 Hyperinflated NAD NAD NAD 2days 2days N
P45L50E4 Hyperinflated NAD NAD NAD 4 Days 4 days N
P30L60E8 Hyperinflated NAD NAD NAD 6 days 6days N
P89L21E8 Hyperinflated NAD NAD NAD 3 days 3 days N
P50L45E0 Hyperinflated NAD NAD NAD 6 days 6 days N
P20L70E2 Hyperinflated NAD NAD NAD 3 days 3 days N
P30,L56,E4 Hyperinflated NAD NAD NAD 3 days 3 days N
P72,L19,E5 Hyperinflated NAD NAD NAD 5 days 5 days N
P56,L36,E3 Hyperinflated NAD NAD NAD 3 days 3 days N
P55,L40,E3 Hyperinflated NAD NAD NAD 3 days 3 days N
P35,L55,E8
Pneumonic patch in R 
upper lung field NAD NAD NAD 6 days 12 days N
P20,L73,E5 Hyperinflated NAD NAD NAD 3 days 3 days N
P64,L32.E2 Hyperinflated NAD NAD NAD 3 days 3 days N
S.no Group Name Age Sex Address IP. No.
Date of 
admission
57 C Dhanuksha 11 months F Omalur 38884 29.5.16
58 A Tamilarasi 3 months F Thattambatti 40437 2.6.16
59 B Kathirvel 6 months M Tiruchengodu 40463 12.6.16
60 A Harini 6 months F Tammanaiakkampatti 38708 14.6.16
61 A Haridhar 4 months M kichipalayam 36550 16.6.16
62 B Madhan 3 months M Namakkal 40179 20.6.16
63 C Alagesan 11 months M A D street 41127 20.6.16
64 C Deepadharshan 12 months M Kondalampatti 42768 23.6.16
65 B Yukesh 7 months M Omalur 13643 23.6.16
66 C Varshini 3 months F Muthmpati gate 42769 23.6.16
67 A Krithikesh 3 months M Kichipalayam 42857 26.6.16
68 B Darshan 2 months M Vadapatti 44129 26.6.16
69 A Poornima 6 months F kandhampatti 30331 30.6.16
70 A Srepriya 5 months M Pachapatti 24632 30.6.16
71 B Kavya 6 months F Kondalampatti 45518 1.07.16
72 C Saicharan 11 months M settichavadi 46713 1.7.16
73 C Kanisk 12 months M Omalur 48731 2.7.16
74 B Karthick 9 months M Nethimedu 46547 2.7.16
75 C B/o Sundari 3 months M Valapadi 47856 4.7.16
76 A Jeeva 2 months M Omalur 44989 4.7.16
77 B Saranya 3 months F Kichipalayam 45092 6.7.16
78 B Hari 8 months M cudalore 43630 6.7.16
79 A Sabari 2 months M Anathanapatti 45216 7.7.16
80 C Akshya 4 months F kicchipalayam 41136 8.7.16
81 C Venkat 9 months M Jagirchinmapalayam 46774 8.7.16
82 A Gayathri 4 months F Sanyasikundu 40265 8.7.16
83 A Shankar 4 months M Ammapet 40131 9.7.16
84 C Surendar 11 months M Gugai 49906 9.7.16
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P75,L23,E1 Hyperinflated NAD NAD NAD 3 days 3 days N
P46,L40,E2 Hyperinflated NAD NAD NAD 4 Days 4 days N
P55,L40,E3 Hyperinflated NAD NAD NAD 6 days 6 days N
P70,L21,E6
Pneumonic patch in r 
lower lobe NAD NAD NAD 3 days 3 days N
P72,L19,E5
Pneumonic patch in R 
upper lung field NAD NAD NAD 6 days 8 days N
P55,L40,E3 Hyperinflated NAD NAD NAD 5 days 5 days N
P35,L60,E3 Hyperinflated NAD NAD NAD 3 days 3 days N
P48,L45,E3 Hyperinflated NAD NAD NAD 6 days 6 days N
P70,L26,E2 Hyperinflated NAD NAD NAD 6 days 6 days N
P38,L61,E1 Hyperinflated NAD NAD NAD 6 days 10 days N
P35,L60,E3 Hyperinflated NAD NAD NAD 6 days 6 days N
P35,L60,E2 Hyperinflated NAD NAD NAD 2 days 2 days N
P50,L45,E2 Hyperinflated NAD NAD NAD 6 days 6 days N
P20,L70,E2 Hyperinflated NAD NAD NAD 3 days 3 days N
P55,L40,E3 Hyperinflated NAD NAD NAD 6 days 18 days N
P35,L60,E3 Hyperinflated NAD NAD NAD 3 days 3 days N
P48,L45,E3 Hyperinflated NAD NAD NAD 6 days 8 days N
P20,L71,E6 Hyperinflated NAD NAD NAD 3 days 3 days N
P38L61E1 Hyperinflated NAD NAD NAD 6 days 6 days N
P35,L60,E3 Hyperinflated NAD NAD NAD 6 days 6 days N
P40,L54,E2 Hyperinflated NAD NAD NAD 3 days 3 days N
P72,L19,E5 Hyperinflated NAD NAD NAD 5 days 5 days N
P50,L45,E3 Hyperinflated NAD NAD NAD 6 days 6 days N
P80,L15,E4
Pneumonic patch in R 
upper lung field NAD NAD NAD 11 Days 11 days N
P20,L73,E5
Pneumonic patch in L 
upper lung field NAD NAD NAD 3 days 18 days N
P14,L74,E10 Hyperinflated NAD NAD NAD 5 days 5 days N
P89L21E8 Hyperinflated NAD NAD NAD 3 days 3 days N
P36,L60,E4 Hyperinflated NAD NAD NAD 3 days 3 days N
S.no Group Name Age Sex Address IP. No.
Date of 
admission
85 C Saranya 9 months F Omalur 46469 10.7.16
86 A Dinesh 4 months M Ammapet 50131 11.7.16
84 C Surendar 11 months M Gugai 49906 9.7.16
88 A Vinoth 10 months M Kalarampatty 45716 12.7.16
89 C srihari 4 months M Ammapet 40131 12.7.16
90 C priya 6months F Kichipalayam 40658 14.7.6
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P20,L73,E5 Hyperinflated NAD NAD NAD 3 days 3 days N
P89L21E8 Hyperinflated NAD NAD NAD 3 days 3 days N
P36,L60,E4 Hyperinflated NAD NAD NAD 3 days 3 days N
P10,L81,E6 Hyperinflated NAD NAD NAD 4 Days 4 days N
P89L21E8 Hyperinflated NAD NAD NAD 3 days 3 days N
P72,L19,E5 Hyperinflated NAD NAD NAD 5 days 5 days N
